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1 Introduction 
1.1 Pituitary gland 
1.1.1 Anatomy of Pituitary gland  
The pituitary gland is a small (pea-sized in humans) endocrine gland, lies in close proximity to 
the hypothalamus at the base of brain, and is protected by a bony cavity structure of the 
sphenoid bone called sella turcica (also known as Turkish saddle) (Figure 1). The pituitary 
gland is regulated by the central nervous system to control normal homeostasis through 
neuroendocrine pathways involving the hypothalamus. By feedback effects from peripheral 
target gland hormones, the hypothalamus secretes stimulatory and inhibitory hormones to 
regulate pituitary gland function. Under control of hypothalamus, the pituitary gland is a central 
regulator, responsible for the producing trophic hormones, and these hormones affect 
peripheral endocrine glands which are essential for growth, reproduction, metabolism, 
development, adaptation to external environmental changes, and stress. 
The pituitary gland is composed of three compartments which are anterior (adenohypophysis), 
posterior (neurohypophysis) and intermediate lobe. The anterior pituitary arises from a 
depression in the dorsal wall of the pharynx (stomodial part) known as Rathke's pouch 
(Kelberman and Dattani 2007). It consists of two anatomical regions known as the pars 
tuberalis and pars distalis. The pars distalis represents the majority of the anterior pituitary and 
is where the pituitary hormone production occurs. The function of the anterior pituitary is to 
synthesize and secrete important endocrine hormones, such as adrenocorticotropic hormone 
(ACTH), thyroid-stimulating hormone (TSH), prolactin (PRL), growth hormone (GH), follicle-
stimulating hormone (FSH), and luteinizing hormone (LH). These hormones are produced by 
specific types of endocrine cells, and work on target glands or tissues, regulating 
corresponding release of hormones and several processes of human physiology (Table 1). 
The anterior pituitary itself is regulated by hypothalamic hormones which are transported from 
hypothalamus by a system of blood vessels called hypothalamo-hypophyseal portal system. 
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Table 1. Anterior pituitary hormones and their control (Nussey and Whitehead 2001) 
Hormone 
Target 
organs 
Effect 
Seretory cell 
types  
(% of pituitary 
cell population) 
Hypothalamic 
hormone 
Predominant 
hypothalamic 
nucleus of 
synthesis 
Adrenocorticotropic 
hormone (ACTH) 
Adrenal 
gland 
Stimulates  
glucocorticoids; induces 
stress response 
Corticotroph 
(15%-20%) 
CRH (+) 
Paraventricular, 
supraoptic 
Growth hormone 
(GH) 
Liver; 
adipose 
tissue 
Stimulates IGF-1; 
promotes bone and 
muscle growth; lipid and 
carbohydrate metabolism 
Somatotroph 
(40%-50%) 
GHRH (+) 
Somatostatin (-) 
Arcuate, 
anterior 
periventricular 
Prolactin (PRL) 
Ovary, 
mammary 
gland 
Stimulates 
estrogens/progesterone; 
milk production 
Lactotroph 
(10%-25%) 
TRH (+) 
Dopamine (-) 
Arcuate, 
paraventricular 
Luteinizing hormone 
(LH) 
 
Follicle-stimulating 
hormone (FSH) 
Gonads 
Stimulates sex hormones; 
regulates the 
development, growth, 
pubertal maturation of the 
reproductive system 
Gonadotroph 
(10-15%) 
GnRH (+) Arcuate 
Thyroid-stimulating 
hormone (TSH) 
Thyroid 
gland 
Stimulates thyroid 
hormone; regulates thyroid 
function 
Thyrotroph  
(3%-5%) 
TRH (+) 
Somatostatin (-) 
Paraventricular, 
anterior 
periventricular 
CRH, Corticotropin-releasing hormone; GHRH, growth-hormone-releasing hormone; TRH, Thyrotropin-releasing 
hormone; GnRH, Gonadotropin-releasing hormone. (+), stimulatory; (-), inhibitory.  
Among the endocrine cells scattered pluripotent progenitor cells, stem cells, and 
folliculostellate cells (FS cells) (Landolt, et al. 2006). FS cells are of neuro-ectodermal origin, 
and represent 5% of anterior pituitary cell population (Landolt, et al. 2006). They are 
immunopositive for S-100 protein and glial fibrillary acidic protein (GFAP), and are 
characterized by their star-like morphology and their ability of forming follicles (Allaerts and 
Vankelecom 2005; Jin, et al. 2001; Kagayama 1965; Rinehart and Farquhar 1953). They not 
only act as supporting cells for the endocrine cells, but also offer an intrapituitary 
communication system through gap junctions and their long cytoplasmic processes surround 
the neighboring endocrine cells (Acosta, et al. 2010; Fauquier, et al. 2001; Inoue, et al. 1999; 
Morand, et al. 1996). FS cells do not produce hormones but express interleukin-6 (IL-6), basic 
fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), transforming 
growth factor-beta (TGF-), platelet-derived growth factor-A (PDGF-A), PDGF-B and some 
cytokine and hormone receptors, suggesting that they are implicated in regulation of hormone 
secretion, angiogenesis promotion, formation and permeability of blood vessels by auto- and 
paracrine manner (Inoue, et al. 1999; Kowarik, et al. 2010; Lohrer, et al. 2001; Lohrer, et al. 
2000; Renner, et al. 2009; Renner, et al. 2002; Vlotides, et al. 2009). 
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The posterior pituitary gland develops by the evagination of neural tissue from the floor of the 
third ventricle (Mehta and Dattani 2008). It is mainly composed of the terminals of the distal 
axons which extend from the magnocellular neurons of supraoptic and paraventricular nuclei 
in hypothalamus. Besides axons, the posterior pituitary also contains glial cells called 
pituicytes which surround the axon projections. Two hormones named oxytocin and arginine 
vasopressin (AVP) are produced by the hypothalamus and theses hormones are transported 
through extended axons to the posterior pituitary where they are stored and released as 
required under hypothalamic control (di Iorgi, et al. 2009). Pituicytes were reported to regulate 
the release of these two hormones by morphological changes (Rosso and Mienville 2009; 
Theodosis 2002). Oxytocin increases the uterine contraction during labor and stimulates 
lactation, and recently, some studies have shown the implication of oxytocin in social memory 
and attachment, sexual and maternal behavior, human bonding and trust, and aggression 
(Lee, et al. 2009). AVP is involved in regulating body’s retention of water. Additionally, AVP 
has primarily been implicated in male-typical social behaviors, including aggression and pair-
bond formation, and in stress-responsiveness (Heinrichs, et al. 2009). 
The intermediate lobe, which is the part between anterior pituitary and posterior pituitary, is 
derived from oral ectoderm together with the anterior pituitary (Mehta and Dattani 2008). It 
mainly contains melanotroph cells, which produce pro-opiomelanocortin (POMC) and release 
processed POMC products such as -endorphin and -melanocyte stimulating hormone 
(MSH) (Bicknell 2008; Saland 2001). In humans, in contrast to the mouse, the intermediate 
lobe largely disappears during embryogenesis, and fuses with the anterior lobe soon after 
birth, thought to be represented in the adult by cysts at the junction of anterior and posterior 
lobes (Kelberman, et al. 2009; McNicol 1986; Rasmussen 1930). The function of the 
intermediate lobe as defined in animals has no discrete anatomical location within human 
pituitary gland (McNicol 1986).  
The pituitary stalk is the bridge between hypothalamus and pituitary gland, carrying neural and 
vascular connections, responsible for delivering hypothalamic hormones to the anterior 
pituitary and neural tracts from the hypothalamic nuclei to the posterior pituitary (Kelberman, 
et al. 2009; Mehta and Dattani 2008).  
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Figure 1. Anatomy and blood supply of pituitary gland. The pituitary gland is located 
below the hypothalamus, sitting in the sella turcica of sphenoid bone. It contains three 
parts: anterior, posterior and intermediate lobe. The hypothalamic trophic hormones which 
target endocrine cells in the anterior pituitary are produced by neurosecretory cells in the 
hypothalamus. The terminals of these neurosecretory cell axons reach to the median 
eminence capillaries, where the hormones are transported to and released into the 
anterior pituitary by portal blood system. The posterior hormones are produced by the 
magnocellular neurons in the hypothalamus and are released into the posterior pituitary 
through the extending magnocellular neuron axons. The secreted pituitary hormones 
diffuse into the systemic blood circulation through capillaries net work in the anterior and 
posterior pituitary. 
1.1.2 Blood supply and vascularization of pituitary gland 
The pituitary gland is highly vascularized and gains blood supply through the hypothalamo-
hypophyseal portal system (Figure 1). The capillaries of the hypothalamo-hypophyseal portal 
system are characterized by fenestrated endothelia, improving the delivery and diffusion of 
hormones (Nussey and Whitehead 2001). A separate branch of the internal carotid artery 
called superior hypophysial artery, which ascends from cavernous sinus, delivers the arterial 
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blood into portal capillary beds in the median eminence, and then reaches the pars distalis of 
anterior pituitary through the long portal veins that descend along the pituitary stalk, and 
interconnect the portal capillary beds and capillary beds inside the pars distalis (Leclercq and 
Grisoli 1983). In addition, approximately 30% of the total blood supply to the anterior pituitary 
is from the venous blood draining from the posterior pituitary through the short portal veins 
(Gross, et al. 1993). The pars distalis of anterior pituitary receives little or no arterial blood 
supply from the internal carotid artery (Bergland and Page 1978; Leclercq and Grisoli 1983). 
Rapidly enhanced magnetic resonance images (dynamic MRI) showed in man that the 
perfusion sequence of arterial blood first reached the posterior pituitary and the median 
eminence, followed by venous drainage to the anterior pituitary (Yuh, et al. 1994). The venous 
blood drainage from the anterior pituitary flows into systemic circulation trough the 
adenohypophysial veins (Bergland and Page 1978). This blood flow pattern allows anterior 
pituitary to collect both hypothalamic factors and posterior information. The posterior pituitary 
is fed by the inferior hypophyseal artery branches distributing in the cavernous sinus. The 
venous drainage from the posterior pituitary goes into the neurohypophysial veins besides the 
short portal veins, and then enters the venous circulation.  
Some studies about activators contributing to the angiogenesis and vascularization of pituitary 
gland have been performed. VEGF, which is a well known angiogenic factor, has been 
localized mainly in corticotroph, somatotroph and folliculostellate cells (Lloyd, et al. 1999; Vidal, 
et al. 1999; Yamamoto, et al. 1999). A study in rat using FITC-labeled gelatin injection, 
immunohistochemistry and in-situ RT-PCR showed that VEGF is involved in development of 
primary capillaries in median eminence and vascularization of pars distalis (Nakakura, et al. 
2006). Pituitary autotransplantation demonstrated that VEGF expression in pituitary is not 
critical under hypothalamic control and hypoxia may play a crucial role in the induction of 
VEGF expression in the non-tumorous pituitary (Lombardero, et al. 2006). Leptin, which was 
reported to have a significant role in induction of neovascularization, is also expressed in 
pituitary gland, suggesting that it could play a role in pituitary angiogenesis (Cao, et al. 2001; 
Lloyd, et al. 2001; Ribatti, et al. 2007a). The mouse pituitaries with Prop1 (Prophet of pituitary 
transcription factor 1) gene mutations are poorly vascularized and dysmorphic, with a striking 
elevation in apoptosis, indicating that Prop 1 is implicated in pituitary vascularization during 
the pituitary development (Ward, et al. 2006). bFGF, a stimulator of angiogenesis, has been 
shown to be localized in gonadotroph cells, FS cells and endothelial cells in the anterior 
pituitary, and is released by cellular disruption during pituitary vascular development in rats 
(Schechter, et al. 1996; Schechter, et al. 1993). 
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1.2 Pituitary adenomas 
Pituitary adenomas, arising from adenohypophysial cells, are the most common tumors in the 
sella region. The majority of pituitary adenomas grow slowly, and are defined as benign 
because of the absence of metastases, but some exhibit a faster growth pace and can be 
highly invasive (Kovacs, et al. 2001). About 15–25% of cases demonstrate tumor invasion into 
the hypophysis or cavernous sinus at initial diagnosis (Yoshida and Teramoto 2007). Pituitary 
adenomas may cause serious health problems due to either compression of neighboring 
tissues (i.e. visual nerve) or major changes in endocrine homeostasis resulted from the 
hormone excess syndromes they cause. It is difficult to determine the true incidence of the 
pituitary adenomas, because they are often asymptomatic (Swearingen and Biller 2008b). 
They are present in approximately 16.9% of the general population, and represent up to 25% 
of all intracranial tumors (Ezzat, et al. 2004; Oberholtzer 1999). There are no significant 
differences in the frequency of pituitary adenomas between men and women, if the types are 
ignored and both surgically and autopsy obtained tissues are combined (Kovacs, et al. 2001). 
Although rarely diagnosed in prepubertal age, pituitary adenomas can be found in every age 
group, from infancy to senescence (Kovacs, et al. 2001).The prevalence, which increases with 
advancing age, is about 14% and 22% in postmortem and imaging studies, respectively 
(Swearingen and Biller 2008b). 
Pituitary adenomas can be classified in various ways, such as functional, anatomic/radiologic, 
histologic, immunohistochemical, ultrastructural, and clinicopathologic (Asa and Ezzat 2009). 
The functional classification, based on hormonal activity,  divides pituitary adenomas into six 
groups: ACTH-producing adenomas, linked to Cushing disease and Nelson’s syndrome; GH-
producing adenomas, linked to acromegaly and/or gigantism; PRL-producing adenomas, 
linked to hyperprolactinemia, TSH-producing tumors linked to thyroid dysfunction; rare 
clinically detectable gonadotroph adenomas, linked to hypogonadism due to paradoxical 
down-regulation of function; non-functioning adenomas, clinically endocrinologically inactive 
adenomas, unaccompanied with detectable hormone activity (Asa and Ezzat 2009; Kovacs, et 
al. 2001). The anatomic/radiologic classification is based on size and degree of local invasion. 
On the basis of their size, pituitary adenomas can be separated into macroadenomas with 
more than 10 mm in their largest diameter and microadenomas with less volume (Kovacs, et 
al. 2001). The histologic classification is based on the tinctorial characteristics of the cell 
cytoplasm, and separates pituitary adenomas into acidophilic, basophilic and chromophobic 
tumors (Asa and Ezzat 2009; Kovacs, et al. 2001). This classification has limited value, since 
it fails to take into consideration hormone production, cellular derivation and structure–function 
relationship, and has been largely abandoned (Kovacs, et al. 2001). The 
immunohistochemical classification is based on the detection of antigens in tissue, providing 
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the information primarily about hormone content, additionally about transcription factors and 
keratins (Asa and Ezzat 2009; Kovacs, et al. 2001). The ultrastructural classification with 
application of electron microscopy is based on subcelluar features of cell differentiation. The 
electron microscopy provides conclusive information on the cellular composition and secretory 
activity of the tumor, and it’s a very valuable tool for research. However, the ultrastructural 
investigation is time consuming, expensive and has difficulties in correct diagnosis (Asa and 
Ezzat 2009; Kovacs, et al. 2001). Clinicopathologic classification, based on both 
morphological and clinical features, is most effective and practical (Table 2).  
       Table 2. Clinicopathological classification of pituitary adenomas (Asa and Ezzat 2009) 
Functioning adenomas Non-functioning adenomas 
GH-PRL-TSH family 
Adenomas causing GH excess  
Densely granulated somatotroph adenomas  
Sparsely granulated somatotroph adenomas Silent somatotroph adenomas 
Mammosomatotroph adenomas  
Adenomas causing hyperprolactinemia  
Lactotroph adenomas Silent lactotroph adenomas 
Acidophil stem cell adenomas  
Adenomas causing TSH excess  
Thyrotroph adenomas Silent thyrotroph adenomas 
ACTH family 
Adenomas causing ACTH excess  
Densely granulated corticotroph adenomas Silent corticotroph adenomas (Type I) 
Sparsely granulated corticotroph adenomas Silent corticotroph adenomas (Type II) 
Gonadotroph family 
Adenomas causing gonadotropin excess  
Gonadotroph adenomas 
Silent gonadotroph adenomas (null-cell 
adenomas, oncocytomas) 
Unclassified adenomas 
Unusual plurihormonal adenomas Immunonegative adenomas 
ACTH, adrenocorticotropin; GH, growth hormone; PRL, prolactin; TSH, thyrotropin-stimulating hormone. 
1.2.1 Prolactinomas 
Prolactinomas (also known as lactotroph adenomas) are the most common type of pituitary 
adenomas. It arises from lactotroph cells of anterior pituitary, secreting prolactin (PRL). They 
comprise 45% of the clinical pituitary tumor cases with an incidence of 6 to 10 per million per 
year and a prevalence of 60 to 100 cases per million in clinical series (Ciccarelli, et al. 2005). 
Prolactinomas are the most frequent cause of PRL excess, and usually the most relevant 
clinical manifestations are infertility, gonadal and sexual dysfunction in both sexes (Gillam, et 
al. 2006; Schlechte 2003). The number of these tumors in surgical series is very low, due to 
the success of dopamine agonist therapy.  
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There are three variants of prolactinomas: sparsely granulated and densely granulated 
lactotroph adenomas and the rare, but aggressive, acidophil stem cell tumor (Asa and Ezzat 
2009). The most common variant is sparsely granulated lactotroph adenomas which consist of 
chromophobic tumor cells (Asa and Ezzat 2009). Immunohistochemistry shows strong 
immunostaining for PRL with paranuclear globular pattern corresponding to the Golgi area 
(Asa and Ezzat 2009). Densely granulated lactotroph adenomas are much less common than 
the sparsely granulated variant (Asa and Ezzat 2009). Differing from the sparsely granulated 
adenomas, these tumors cells are acidophilic and show diffuse cytoplasmic positivity for PRL 
(Asa and Ezzat 2009). The acidophil stem cell adenomas are composed of oncocytic cells 
with large cytoplasmic vacuoles corresponding to giant mitochondria (Asa and Ezzat 2009). 
These tumors may have an unusual bihormonal profile with diffuse immunoreactivity for PRL 
and scant immunoreactivity for GH (Asa and Ezzat 2009).  
1.2.2 Somatotroph adenomas 
Somatotroph adenomas, which arise from GH-producing cells, account for 10~15% of pituitary 
adenomas (Asa and Ezzat 2009). GH hypersecreting tumors cause gigantism in young 
patients and acromegaly in adults (Asa and Ezzat 2009). The incidence of acromegaly is 
about 2 to 4 per million with a mean age at presentation of 40–50 years (Ciccarelli, et al. 
2005). Morphologically, the majority of these tumors are macroadenomas and frequently have 
suprasellar growth and expansion to the lateral sellar wall (Swearingen and Biller 2008b).  
The subtypes of these adenomas include densely granulated, sparsely granulated 
somatotroph adenomas and mammosomatotroph adenomas (Swearingen and Biller 2008b). 
Densely granulated somatotroph adenomas are the most common finding in adult acromegaly, 
and mammosomatotroph adenomas that produce both GH and PRL are the most frequent 
findings in childhood-onset gigantism and in young patients with acromegaly (Asa and Ezzat 
2009). Both of these two types of adenomas express -subunit, and resemble normal 
somatotroph and mammosomatotroph cells (Asa and Ezzat 2009). They are characterized by 
acidophilic and densely granulated cytoplasm, strong and diffuse cytoplasmic 
immunoreactivity for GH, and strong nuclear immunoreactivity for Pit-1 (pituitary transcription 
factor-1) (Asa and Ezzat 2009; Kovacs, et al. 2001). The immunohistochemistry shows that 
the low molecular weight cytokeratins (CAM 5.2) in densely granulated somatotroph 
adenomas cells are of diffuse cytoplasmic pattern (Asa and Ezzat 2009; Kovacs, et al. 2001; 
Swearingen and Biller 2008b). In contrast, the sparsely granulated somatotroph adenomas 
with chromophobic and less granular cytoplasm have weak and focal GH immunoactivity and 
the staining for -subunit is not identified (Asa and Ezzat 2009; Swearingen and Biller 2008b). 
The immunostaining for CAM 5.2 shows dot-like juxtanuclear aggresome corresponding to the 
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fibrous body (Asa and Ezzat 2009; Swearingen and Biller 2008b). However, they are usually 
nuclear immunopositive for Pit-1 like densely somatotroph adenomas (Asa and Ezzat 2009). 
1.2.3 Corticotroph adenomas 
The corticotroph adenomas which arise from ACTH-producing corticotroph cells comprise 
about 10%~15% of clinical cases of pituitary adenomas (Asa and Ezzat 2009). ACTH is 
overproduced by corticotroph adenomas which cause an excessive release of adrenal 
glucocorticoids leading to the different symptoms of Cushing’s disease. The majority of 
corticotroph adenomas are microadenomas, softer and paler than the normal gland 
(Swearingen and Biller 2008b). Three variants of corticotroph adenomas are known: densely 
granulated corticotroph adenomas, sparsely granulated corticotroph adenomas and Crooke’s 
cell adenomas (Swearingen and Biller 2008b). Cushing’s disease is mostly caused by densely 
granulated cortocotroph adenomas, which have densely granulated basophilic cytoplasm 
apparent with the classical hematoxylin and eosin stain (Asa and Ezzat 2009; Swearingen and 
Biller 2008b). The cytoplasm is also strongly PAS (Periodic acid-Schiff stain)-positive 
(Swearingen and Biller 2008b). The macroadenomas with lower florid hormone excess in 
patients are less common, and have sparsely granulated chromophobic cytoplasm and are 
less PAS-positive (Asa and Ezzat 2009; Swearingen and Biller 2008b). They may be 
associated with Nelson’s syndrome in patients who have undergone bilateral adrenalectomy 
as treatment for pituitary Cushing’s disease without initial identification of a discrete lesion 
(Asa and Ezzat 2009). The Crooke’s cell adenomas are rare. The normal corticotroph cells 
respond to high levels of glucocorticoids by developing Crooke’s hyalinization corresponding 
to intracytoplasmic accumulation of cytokeratins 7 and 8, which are intermediate filaments on 
electron microscopy (Asa and Ezzat 2009; Swearingen and Biller 2008b). Usually the 
corticotroph adenomas don’t have this marker of feedback suppression by glucocorticoids; 
however, the Crooke’s adenomas have the same change as nontumorous corticotroph cells 
(Asa and Ezzat 2009; Kovacs and Horvath 1986; Swearingen and Biller 2008b). They can be 
associated with Cushing’s disease as well (Asa and Ezzat 2009).  
1.2.4 Thyrotroph adenomas 
The thyrotroph adenomas are rare and make up to 1% of pituitary adenomas (Asa and Ezzat 
2009). They can be associated with hyperthyroidism or hypothyroidism, but the majority are 
clinically nonfunctioning (Asa and Ezzat 2009; Swearingen and Biller 2008b). The thyrotroph 
adenomas in general are macroadenomas and invasive, and mass effects with visual-field 
disturbances are common (Asa and Ezzat 2009). The tumor cells are chromophobic and can 
have small cytoplasmic granules with PAS stain (Swearingen and Biller 2008b). 
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Immunohistochemistry shows positivity for TSH and variable staining for -subunit; some also 
express GH and PRL (Swearingen and Biller 2008b). Characteristically, the tumor cells with 
significant nuclear pleomorphism have a polygonal or elongated shape and resemble 
nontumorous thyrotroph cells (Asa and Ezzat 2009). 
1.2.5 Gonadotroph adenomas 
The gonadotroph adenomas comprise the majority of clinically nonfunctioning adenomas 
(Swearingen and Biller 2008b), and clinical manifestations of gonadotropin excess are rare. 
The elevated serum FSH level induced by the gonadotroph adenomas led to ovarian 
enlargement in a 10-year old girl (Tashiro, et al. 1999). A case of clearly high circulating 
immunoreactive FSH due to a functioning FSH-secreting gonadotroph adenoma in a man with 
the MEN 1 syndrome was also reported (Sztal-Mazer, et al. 2008). The tumor cells exhibit 
strong nuclear staining with SF-1 (steroidogenic factor-1), but variable and often only focal 
positive reaction for -subunit, -FSH, and -LH, and show variable degrees of differentiation 
(Asa and Ezzat 2009). Well-differentiated tumor cells are elongated, with the nucleus 
occupying one pole and secretory granules accumulating at the opposite pole (Asa and Ezzat 
2009). In contrast, poorly differentiated cells are generally ovoid or polygonal and lack polarity 
(Asa and Ezzat 2009). 
1.2.6 Non-functioning adenomas 
The non-functioning adenomas lack detectable hormone activity, and cause no signs or 
symptoms secondary to hormonal hypersecretion by the tumor (Greenman and Stern 2009). 
They typically tend to be present with signs of mass effects such as headaches, visual field 
defects and hypopituitarism, when the tumor has reached the stage of a macroadenoma, and 
are usually large at the time of diagnosis (Greenman and Stern 2009; Snyder 1985). Non-
functioning adenomas comprise roughly 50% of pituitary tumors in surgical series (Saeger, et 
al. 2007). The vast majority of these lesions are actually silent gonadotroph adenomas, 
accounting for 85% of non-functioning adenomas, and they are morphologically and 
pathogenetically identical to functioning gonadotroph adenomas (Asa and Ezzat 2009; 
Greenman and Stern 2009). They are positively stained with FSH, LH and their subunits 
(Greenman and Stern 2009). In a minority of patients, intact gonadotropins, mainly FSH, may 
be detected on basal conditions in vivo, but hormone-related symptoms are rare (Greenman 
and Stern 2009). Based on hormone and transcription factor staining, the non-functioning 
adenomas also include silent somatotroph adenomas, silent prolactinomas, silent thyrotroph 
adenomas and silent corticotroph adenomas (Table 3) (Greenman and Stern 2009). They may 
express hormones but do not secret them, and their lack of clinical manifestation may be 
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attributable to reduced hormonal activity or to synthesis of nonfunctional hormone products 
(Asa and Ezzat 2009; Greenman and Stern 2009). The majority are the silent corticotroph 
adenomas which express ACTH (Greenman and Stern 2009). The silent type 3 adenomas 
may express several pituitary hormones and transcription factors (Greenman and Stern 2009). 
Poorly differentiated gonadotroph adenomas cells are often classified as null-cell or 
undifferentiated adenomas because of focal or weak immunoreactivity, but they are positive 
stained with SF-1 and can secret gonadotropins in vitro, indicating their gonadotroph origin 
(Asa and Ezzat 2009; Greenman and Stern 2009). The truly null cell adenomas stain 
negatively both to pituitary hormones and transcription factors (Greenman and Stern 2009). 
Additionally, most oncocytomas represent silent gonadotroph adenomas with extensive 
oncocytic change (Asa and Ezzat 2009). 
Table 3. Clinicopathological classification of non-functioning adenomas (Greenman and Stern 2009) 
             Tumor Type Transcription factors Hormone staining 
Silent gonadotroph adenomas SF-1, GATA-2, ER -FSH, -LH, -subunit 
Silent somatotroph adenomas Pit-1 GH 
Silent prolactinomas Pit-1, ER PRL 
Silent thyrotroph adenomas Pit-1, TEF, GATA-2 -TSH, -subunit 
Silent corticotroph adenomas Tpit ACTH 
Null cell adenomas None None 
Silent subtype 3 adenomas  Multiple 
SF-1, steroidogenic factor-1; ER, estrogen receptor; Pit-1, pituitary transcription factor-1; TEF, thyrotropin 
embryonic factor; GATA-2, GATA binding protein-2; Tpit-1, T-box transcription factor. 
1.2.7 Plurihormonal adenomas 
Plurihormonal pituitary adenomas are capable of producing more than one hormone (Kovacs, 
et al. 2001). Morphologically, they can be divided into monomorphous and plurimorphous 
tumors (Kovacs, et al. 2001). Monomorphous plurihormonal adenomas consist of one cell 
population which produces two or more hormones, and they can not be explained by a 
common cellular origin (Kovacs, et al. 2001; Swearingen and Biller 2008b). Plurimorphous 
adenomas, representing mixed adenomas, are composed of two or more distinct cell types, 
each producing one hormone (Kovacs, et al. 2001). The 2004 WHO classification includes 
only monomorphous adenomas in the category of plurihormonal adenomas, which excludes 
adenomas with any combination of GH, PRL and TSH, or FSH and LH. By this definition these 
tumors are rare (Swearingen and Biller 2008b). 
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1.2.8 Pituitary carcinomas 
Pituitary carcinomas are defined based on the presence of metastasis (Swearingen and Biller 
2008b). In contrast to the high frequency of local invasion, pituitary adenomas only rarely 
metastasize to distant locations in the central nervous system, lymphnodes, and liver (Asa and 
Ezzat 2009). The pituitary carcinomas represent approximately only 0.2% of operated pituitary 
neoplasms (Swearingen and Biller 2008b). Microscopically, the tumors have different degrees 
of high cell density, pleomorphism, necrosis, and invasion, but all of these characteristics can 
also be found in benign pituitary adenomas (Swearingen and Biller 2008b). 
1.3 Pathogenesis of pituitary adenomas 
The pathogenesis of pituitary adenomas has been intensively studied, but the exact 
mechanisms involved in pituitary cell transformation and tumorigenesis is still unclear. X-
chromosomal inactivation analysis demonstrated that pituitary adenomas arise from the 
replication of a single transformed pituitary cell, indicating that they are monoclonal neoplasms 
(Alexander, et al. 1990; Gicquel, et al. 1992; Herman, et al. 1990; Schulte, et al. 1991). This 
observation also suggests that the tumor formation results from the growth advantage 
characteristics of the monoclonal transformed pituitary cell with either activation of proto-
oncogenes or inactivation of tumor-suppressor genes. 
A lot of etiologic factors involved in pituitary tumor formation have been extensively studied, 
including genetic abnormalities in pituitary tumors, over-expression of proto-oncogenes and 
proliferative signals, down-regulation of tumor suppressor genes and inhibitory signals, and 
hormonal dysregulation.  
1.3.1 Genetic abnormalities of proto-oncogenes and anti-proliferative signals 
Many common genetic defects in proto-oncogenes which occur frequently in human 
malignancies are not identified in most of pituitary adenomas (i.e. abnormalities of the Ras-
family).  
The mutations in the gene encoding the  subunit of Gs (GNAS1) frequently appear in about 
30~40% GH-secretion adenomas, leading to constitutively active cAMP-dependent pathway 
(Landis, et al. 1989; Vallar, et al. 1987). However, these mutations infrequently occur in other 
tumors, i.e., in about 10% of non-functioning pituitary adenomas and less than 5% of ACTH-
secreting adenomas (Tordjman, et al. 1993; Williamson, et al. 1995).  
The aberrant expression of an N-terminally truncated variant of fibroblast growth factor (FGF) 
receptor-4 (ptd-FGFR4) has been detected in 40% of pituitary adenomas, and ptd-FGFR4 is 
constitutively phosphorylated in the absence of ligand and transformation in vitro and in vivo 
(Ezzat, et al. 2002).  
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Germline mutations of the tumor suppressor gene MEN1 with LOH (loss of heterozygosity) 
inactivate the normal allele in tumors, resulting in familial pituitary adenomas associated with 
multiple endocrine type 1 (MEN1) (Chandrasekharappa, et al. 1997). However, MEN1 
mutations rarely occur in sporadic pituitary adenomas (Prezant, et al. 1998; Wenbin, et al. 
1999; Zhuang, et al. 1997), although LOH have been found in the region of MEN1 gene in 
10~30% of sporadic pituitary adenomas and the expression of Menin is down-regulated in 
high percentage of cases with or without LOH. Therefore, allelic loss may be responsible for 
the lower menin levels in some, but not all, cases with low menin expression, and post-
transcriptional mechanisms may be involved (Tanaka, et al. 1998; Theodoropoulou, et al. 
2004).  
Germline Inactivating mutations in the aryl hydrocarbon receptor (AHR) interacting protein 
(AIP) gene with LOH of the normal allele in familial presentation of somatotroph adenomas 
and prolactinomas have been reported (Vierimaa, et al. 2006). However, AIP mutations have 
not been identified in sporadic pituitary adenomas (DiGiovanni, et al. 2007).  
Germline mutations in protein kinase-A (PKA) regulatory subunit 1 gene PRKAR1 are 
responsible for Carney’s complex, an autosomal dominant disorder associated with 
somatotroph adenomas and other endocrine tumors (Kirschner, et al. 2000a; Kirschner, et al. 
2000b). However, no mutations of this gene were found in sporadic pituitary adenomas, 
although significantly reduced protein expression of this gene was shown in non-functioning 
and somatotroph adenomas (Kaltsas, et al. 2002; Lania, et al. 2004; Mantovani, et al. 2005; 
Sandrini, et al. 2002; Yamasaki, et al. 2003).  
1.3.2 Over-expression of proto-oncogenes and proliferative signals 
Cyclin proteins are cell cycle regulators, which promote cell progression by activating cyclin-
dependent kinases (CDKs). It has been shown that cyclin proteins, especially cyclin D1, are 
over-expressed in aggressive non-functioning adenomas without cyclin D1 gene (CCND1) 
amplification, indicating that additional mechanisms are involved in the deregulating of cyclin 
D1 expression in human pituitary tumorigenesis. Moreover, cyclin E is preferentially present in 
corticotroph adenomas (Hibberts, et al. 1999; Jordan, et al. 2000). 
The pituitary tumor transforming gene (PTTG) which is an estrogen-inducible gene 
responsible for chromosomal separation and mitosis during the cell division is mostly over-
expressed in adenomas with a more than 50% increase (up to a 10-fold increase in some 
cases) in non-functioning, GH-, PRL-, and ACTH-producing adenomas compared with normal 
pituitaries, suggesting that PTTG is indeed involved in some manner in pituitary tumorigenesis 
(Zhang, et al. 1999); however, specific mutation of PTTG has not been shown in sporadic 
pituitary adenomas (Dworakowska and Grossman 2009). PTTG mediates the estrogen-
induced up-regulation of growth factors with potent mitogenic and angiogenic activity, such as 
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fibroblast growth factor-2 (FGF-2) (Zhang, et al. 1999). FGF-2 (also known as basic or bFGF) 
is over-expressed in pituitary tumor cells (Ezzat, et al. 1995).  
Akt, the best-characterized phosphorylation target of phosphatidylinositol 3-kinase (PI3K), 
which enhances cell proliferation by activating the serine-threonine kinase mTOR (mammalian 
target of rapamycin) is over-expressed (at both mRNA and protein levels) as well as over-
activated (through phosphorylation) in all pituitary tumors, especially non-functioning pituitary 
adenomas (Musat, et al. 2005; Volarevic and Thomas 2001). 
1.3.3 Down-regulation of tumor suppressors and inhibitory signals 
The retinoblastoma protein (pRb), coded by Rb1 gene, is a main inhibitor of cell cycle 
progression between G1 and S phases. The phosphorylation of the pRb by cyclin/CDK 
complex leads to inactive pRb and thus allowing a cell cycle transit from G1 to S phase (Musat, 
et al. 2004). Additionally, CDK inhibitors (CDKI) including Ink4 family (p15, p16, p18, for CDK4 
and 6) and Kip/cip family (p21, p27, p57 for CDK2) are involved in regulation of cell cycle 
(Musat, et al. 2004). The vast majority of pituitary adenomas (90%) display alterations of the 
pRb pathway. In particular, promoter hypermethylation (resulting in transcription silencing) of 
the p15 (INK4b), p16 (INK4a) and pRb genes was detected in 32~36%, 59~71% and 29~35% 
of pituitary tumors, respectively (Ogino, et al. 2005; Yoshino, et al. 2007). It has been 
demonstrated that p27 (Kip1) protein expression level is lower in all types of pituitary 
adenomas without changes of the mRNA levels compared with normal pituitaries, especially in 
corticotroph adenomas and pituitary carcinomas, suggesting enhanced p27 protein 
degradation (Lidhar, et al. 1999; Yoshino, et al. 2007). 
The pituitary tumor apoptosis gene (PTAG) which is a differentially methylated chromosome 
22 CpG island-associated gene (C22orf3) has been recently identified (Bahar, et al. 2004). It 
has been shown that 80% of the pituitary adenomas failed to express this gene compared with 
normal pituitaries, and in this group approximately 20% showed methylation of the CpG 
islands of the PTAG promoter (Bahar, et al. 2004). The methylation of the promoter was 
invariably associated with loss of transcript expression (Bahar, et al. 2004).  
ZAC, a zinc-finger protein that induces apoptosis and cell cycle, is highly expressed in the 
anterior pituitary gland, and is strongly down-regulated at both mRNA and protein expression 
level in non-functioning adenomas (Pagotto, et al. 2000).    
1.3.4 Endocrine specific mechanisms  
The vast majority of sporadic pituitary adenomas do not show hyperplasia in the surrounding 
tissue, suggesting that hormonal stimulation is not a primary etiologic mechanism in pituitary 
adneomas; however, hormone dysregulation and impaired feedback inhibition may be 
involved in development of the pituitary adenomas, concerning that the differentiation, 
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proliferation and hormone release of the adenohypophysial cells are under the strict control of 
hypothalamic neurohormones and regulated by the feedback mechanisms (Asa and Ezzat 
2009; Swearingen and Biller 2008a).  
High levels of CRH and vasopressin V3 receptors have been detected in ACTH-secreting 
adenomas without identified mutational changes in the genes (de Keyzer, et al. 1998). 
Glucocorticoid hormones regulate corticotroph function through specific negative feedback 
loop, and loss of glucocorticoid feedback might cause Cushing’s disease (Asa and Ezzat 
2009). A germline mutation of glucocorticoid receptor (GR) which results in glucocorticoid 
resistance by diminished ligand binding has been implicated as the cause of pituitary 
Cushing’s disease in a small number of patients (Karl, et al. 1996a). However, rare GR 
mutations have been found in sporadic pituitary corticotroph tumors (Karl, et al. 1996b). 
GH auto-regulation and Insulin-like growth factor-1 (IGF-1) regulate GH secretion through 
negative feedback inhibition (Dworakowska and Grossman 2009). The decreased expression 
of the GH receptors and IGF receptors in 18 somatotroph tumors (both at the mRNA and 
protein level) may be the cause of the continuous secretion of GH from the tumor despite high 
circulation levels of IGF-1 and GH; However, no somatic mutations of GH receptor mRNA was 
detected in that group, indicating that decreased feedback inhibition of GH due to somatic 
mutations of the coding region of the GH receptor is unlikely to be a common factor in the 
pathogenesis of GH-producing adenomas (Kola, et al. 2003). 
Dopamine inhibits prolactin secretion through dopamine 2 receptor (D2R). D2R-deficient mice 
develop lactotroph adenomas, suggesting that inactivating mutations of this receptor might 
contribute to the development of lactotroph adenomas (Asa, et al. 1999). However, no 
mutations in the D2R gene have been found in human prolactinomas, including those 
dopaminergic drug resistant prolactinomas which frequently show a reduction of D2R 
transcript (Caccavelli, et al. 1994; Friedman, et al. 1994). Inactivation of the nerve growth 
factor (NGF) receptor (p75) gene results in D2R loss in dopamine-responsive cells and 
prevents D2R expression by NGF in dopamine-nonresponsive cells, which may account for 
some dopamine resistant prolactinomas (Asa and Ezzat 2009; Fiorentini, et al. 2002). 
The mutations in the thyroid hormone receptor  isoform (TR) causing diminished T3 binding 
resulted in reduced inhibition of TSH secretion in two TSH-secreting adenomas (Ando, et al. 
2001). 
1.4 General overview of angiogenesis 
Angiogenesis is the process of new capillary formation by sprouting or by splitting from pre-
existing blood vessels (Risau 1997).  Angiogenesis by vessel sprouting is a multistep process. 
Firstly, after a stimulatory signal, the basement membrane is degraded by the proteolytic 
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enzymes (such as matrix metalloproteinases (MMPs) and plasminogen activators) released by 
activated endothelial cells (ECs), which leads to the formation of tiny sprouts penetrating the 
perivascular stroma. Next, the ECs at the sprout tip migrate toward the angiogenic stimulus 
and proliferate, whereby the ECs form a tubular structure by cell adhesion molecules which 
establish the polarity, luminal versus abluminal, followed by the formation of capillary loops, 
which leads to the development of functioning circulatory network. Finally, the new vessels are 
stabilized, and this process requires the recruitment of pericytes and vascular smooth muscle 
cells (VSMCs), which is regulated by platelet-derived growth factor (PDGF) (Ribatti, et al. 
2007a; Risau 1997). The non-sprouting angiogenesis is the process of splitting pre-existing 
vessels by transcapillary pillars or posts of extracellular matrix, first described in the embryonic 
lung (Patan, et al. 1996; Risau 1997).  
Angiogenesis is controlled by the balance of proangiogenic and inhibitory stimuli (Ribatti, et al. 
2007b). The quiescence of endothelial cells in the healthy adult organism is maintained by the 
dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli (Ribatti, et 
al. 2007a). Negative regulators may be particularly important in endocrine organs that are very 
vascular, and down-regulation of inhibitor production may be required to activate the 
angiogenic switch (Hanahan and Folkman 1996). Angiogenesis involves a large number of 
endogenous proangiogenic factors including VEGF, FGF-2, IL-8, TGF-PDGF, angiopoietins, 
matrix metalloproteinases, which play important roles in endothelial cell proliferation, vascular 
stabilization, recruitment of inflammatory cells releasing angiogenic factors, or extracellular 
matrix degradation (Li, et al. 2003; Ribatti, et al. 2007a). In addition to metabolic factors such 
as hypoxia, the process of angiogenesis is also regulated by some hormones such as 
estrogen, GH, IGH-1 and TSH through promoting endothelial cell proliferation or increasing 
VEGF production (Hellstrom, et al. 1999; Hyder, et al. 2000; Smith, et al. 1999). Gene 
mutations or down-regulation of tumor suppressor genes such as p53 and VHL facilitate tumor 
angiogenesis by inactivating angiogenesis inhibitors or enhancing angiogenic factors 
(Dameron, et al. 1994; Levine 1997; Teodoro, et al. 2007; Turner, et al. 2002).The 
endogenous inhibitors of angiogenesis include thrombospondin-1, angiostatin, endostatin and 
so on, which inhibit endothelial cell proliferation or matrix metalloproteinases (Ribatti, et al. 
2007a). In pathological situations angiogenesis may be triggered not only by the 
overproduction of proangiogenic factors, but also by the down-regulation of inhibitory factors 
(Ribatti, et al. 2007a). Pathogenic angiogenesis may occur in several diseases such as 
atherosclerosis (O'Brien, et al. 1994), rheumatoid arthritis (Colville-Nash and Scott 1992), 
diabetic retinopathy (Sharp 1995) and psoriasis (Nickoloff, et al. 1994).  
A large number of studies have firmly demonstrated that angiogenesis plays an essential role 
in tumorigenesis, tumor development and progression, besides in physiological processes 
such as embryogenesis, wound healing and the normal menstrual cycle. It is well known that 
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tumors require neovascularization to supply themselves with nutrients, oxygen and also give 
the metabolites access to blood circulation if they are to grow beyond 2 mm3  (Jugenburg, et al. 
1997). It is proposed that increased tumor diameter require a corresponding increase in 
vascularization (Folkman 1972). Tumor invasion of surrounding structures and tumor 
metastasis may occur due to the degradation of extracellular matrix during angiogenesis, and 
the new blood vessels provide a way for metastatic tumor cells to enter the systemic 
circulation (Folkman 1990; Gasparini and Harris 1995). The acquisition of angiogenic 
capability can be regarded as a milestone of progression from neoplastic transformation to 
tumor growth and metastasis (Ribatti, et al. 2007a). Many studies have shown the relationship 
between angiogenesis and tumor behavior; for example, increased angiogenesis has been 
shown to be associated with the development of metastases, poor prognosis, and reduced 
survival in breast, prostate and stomach malignancies (Horak, et al. 1992; Maeda, et al. 1995; 
Turner, et al. 2003; Weidner, et al. 1993; Weidner, et al. 1992; Weidner, et al. 1991).  
Angiogenesis is measured as microvessel density using antibodies against different 
endothelial markers on both frozen and paraffin-embedded sections. Antibodies that are most 
commonly used are against the endothelial antigens factor eight-related antigen (F8), CD31 
(platelet endothelial cell adhesion molecule), CD34, and the lectin ulex europaeus agglutinin 1 
(UEA1) (Turner, et al. 2003). 
1.5 Angiogenesis in pituitary adenomas 
The pituitary, as a central endocrine organ, is highly-vascularized, and in contrast to other 
tumor types such as prostate and breast tumors, which are more vascularized than respective 
normal tissue, pituitary adenomas have been shown of less vascular density compared with 
normal pituitary specimens as measured by different endothelial markers (Horak, et al. 1992; 
Jugenburg, et al. 1995; Schechter 1972; Turner, et al. 2000b; Weidner, et al. 1991). It is not 
simply the benign nature of pituitary adenomas that explains their relatively low vascular 
density, because benign or precancerous breast or cervical lesions are more vascular than 
corresponding normal tissues (Brem, et al. 1978; Dobbs, et al. 1997; Turner, et al. 2003). This 
low vascular density or inhibition of angiogenesis may partly explain why pituitary adenomas 
have relatively low growing speed besides another possible explanation that these relatively 
slow-growing tumors have low metabolic demands that do not require increased 
vascularization (Turner, et al. 2003). 
The neuroradiological and morphological studies suggest that pituitary adenomas receive a 
direct systemic arterial blood supply in contrast to the normal anterior pituitary gland, and 
tumors without arterial supply were described as small (Gorczyca and Hardy 1988; Powell, et 
al. 1974; Schechter, et al. 1988; Yuh, et al. 1994). A potential explanation for the relatively low 
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vascular density of pituitary adenomas is that the indeed increased angiogenesis has led to in-
growth of blood vessels from the systemic circulation and the escape from the hypothalamic 
controlling factors found in the portal circulation (Turner, et al. 2003). In addition, it has been 
shown that the majority of pituitary tumors have capillaries with reduced or even absent 
fenestrations and complete absence or fragmentation of parenchymatous basement 
membrane, and the endothelial cells of the capillaries are swelling and blebbing due to the 
compression of the long portal veins and ischemia along with tumor growth (Farnoud, et al. 
1992; Kovacs and Horvath 1973; Tuffnell, et al. 1991).  
Many activators of angiogenesis, including VEGF and its receptors, FGF and its receptors, 
hypoxia-inducible factor-1 (HIF-1), angiogenin, angiopoietin and Tie2 tyrosine kinase 
receptors, matrix metalloproteinases (MMPs), pituitary tumor transforming gene (PTTG), and 
estrogens, have shown to be associated with pituitary tumor angiogenesis (Lloyd, et al. 2003; 
Turner, et al. 2003). Some studies about therapeutic application of angiogenesis inhibitors 
have been performed. The fumagillin analog TNP-470 and a synthetic MMPs inhibitor 
batimastat have been demonstrated to reduce neovascularization and lactotroph proliferation 
in Fischer 344 rat estrogen-induced prolactinoma model (Mucha, et al. 2007; Stepien, et al. 
1996; Takechi, et al. 1994).  
1.6 Sumoylation and RSUME 
Sumoylation is a form of post-translational modification by SUMO (small ubiquitin-related 
modifier), regulating protein function (Johnson 2004). SUMO, which has four isoforms (SUMO-
1, SUMO-2, SUMO-3, and SUMO-4) belongs to the ubiquitin-like protein family (Wilkinson and 
Henley 2010). SUMO share only ~18% sequence identity with ubiquitin, but the folded 
structure of SUMO is similar with ubiquitin (Bayer, et al. 1998).  During the process of 
sumoylation, SUMO proteins are firstly activated by a thioester linkage with enzyme E1, a 
heterodimer of SAE1 (SUMO-activating enzyme E1) and SAE2 in mammals (Gong, et al. 
1999). Then, SUMO is passed to conjugating enzyme Ubc9 (ubiquitin-conjugating 9), again 
via a thioester linkage (Gong, et al. 1997; Johnson and Blobel 1997; Schwarz, et al. 1998). 
SUMO E3 ligase acts as scaffolds bringing SUMO-loaded Ubc9 into contact with the substrate 
protein or holding the SUMO-Ubc9 thioester in a conformation facilitating SUMO transfer 
(Figure 2) (Alarcon-Vargas and Ronai 2002; Wilkinson and Henley 2010).  
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Figure 2. The SUMO conjugation pathway. SUMO is synthesized as a precursor and 
processed by hydrolases to make the carboxy-terminal double-glycine motif available for 
conjugation. It is subsequently conjugated to proteins by means of E1 activation, E2 
conjugation and E3 ligation enzymes. The E3 enzymes might serve to increase the affinity 
between Ubc9 (E2) and the substrates by bringing them into close proximity in 
catalytically favorable orientations, allowing sumoylation to occur at a maximal rate. 
(Alarcon-Vargas and Ronai 2002) 
Most sumoylation occurs in the nucleus, and has the effects on modulating activity of 
transcription factors negatively or positively, participates in protein nuclear transport, and also 
affects DNA repair and chromosome organization and function (Figure 3) (Alarcon-Vargas and 
Ronai 2002; Johnson 2004). In contrast to ubiquitination that leads to proteasomal 
degradation of proteins, the functional consequences of sumoylation vary greatly from 
substrate to substrate, and in many cases are not understood at molecular level (Johnson 
2004). An increasing number of studies show that sumoylation positively or negatively 
regulates the substrate proteins which are involved in human cancers, such as PML (a nuclear 
body-associated phosphoprotein), IB, Mdm2 and c-Jun (Verger, et al. 2003), suggesting 
that this process may be important in tumorigenesis and development.  
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Figure 3. Functions of sumoylation. Some of the known functions of sumoylation are 
indicated. PML, promyelocytic leukaemia protein. (Alarcon-Vargas and Ronai 2002) 
Frequently sumoylation alters protein function by influencing the interactions of substrates with 
other proteins or with DNA, and this may be achieved by blocking the interaction site, creating 
a new binding face on the substrate to recruit other binding partners, or change in 
conformation of the substrate protein to alter its activity or revealing previously masked 
binding sites (Johnson 2004; Wilkinson and Henley 2010). In addition, sumoylation can block 
ubiquitin binding sites by competing with ubiquitination on the same lysine residue to increase 
protein stabilization (Desterro, et al. 1998).  
RSUME (RWD-containing sumoylation enhancer) has been recently identified in rat pituitary 
lactosomatotroph tumor cell line GH3 (Carbia-Nagashima, et al. 2007). As an E3 enzyme, it 
increases noncovalent binding of SUMO to Ubc9, enhances Ub9-SUMO thioester formation 
and SUMO polymerization, and therefore enhances sumoylation (Carbia-Nagashima, et al. 
2007; Huang, et al. 2007). RSUME is expressed in various tissues, with higher expression in 
cerebellum, pituitary, heart, kidney, liver, stomach, pancreas, prostate, and spleen (Carbia-
Nagashima, et al. 2007). It has been shown that RSUME is induced by hypoxia, and RSUME 
expression is in the necrotic inner zone rather than in the peripheral zone of two gliomas 
(Carbia-Nagashima, et al. 2007). By enhancing sumoylation, RSUME increases IB levels and 
stabilize HIF-1in monkey kidney cell line COS-7 leading to inhibition of NF-B 
transcriptional activity, and increased HIF-1transcriptional activity and VEGF expression 
(Figure 4) (Carbia-Nagashima, et al. 2007).  
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Figure 4. Actions of RSUME on the sumoylation process. RSUME enhances Ubc9-
SUMO thioester formation and facilitates the progression of the SUMO transfer cascade. 
By enhancing sumoylation, RSUME inhibits NF-B activity through the stabilization of IB, 
which leads to the inhibition of its targets, and activates HIF-1 and consequently its 
targets. (Carbia-Nagashima, et al. 2007) 
1.7 Hypoxia-inducible factor 1 (HIF-1)   
HIF-1 plays an essential role in cellular and systemic oxygen homeostasis by adopted oxygen 
sensing mechanism in higher eukaryotes (Lee, et al. 2004). HIF-1 is a heterodimeric 
transcription factor containing the - subunit and - subunit (also known as aryl hydrocarbon 
receptor nuclear translocator (ARNT)), and both belong to bHLH (basic helix-loop-helix)-PAS 
(Per/ARNT/Sim) family (Wang, et al. 1995). The  subunit is stabilized and activated by 
hypoxic conditions and maintained at low levels under normoxia conditions; whereas the 
subunit is constitutively expressed and its activity is not affected by hypoxia (Li, et al. 
1996).HIF-1 dimerizes with HIF-1through bHLH and PAS motifs and binds to the hypoxia 
response element (HRE) of the DNA sequence, which leads to transcription activation (Jiang, 
et al. 1996). Two transactivation domains (TAD), N-terminal (N-TAD) and C-terminal (C-TAD) 
are located in the C-terminal half of the HIF-1(Figure 5) (Ke and Costa 2006; Ruas, et al. 
2002). The N-TAD overlaps with the oxygen-dependent degradation domain (ODDD), and it is 
continuous with protein stability (Cockman, et al. 2000). The C-TAD which is required for full 
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HIF-1 activity has been shown to interact with coactivators such as CBP/p300 to activate gene 
transcription independent of protein stability (Lando, et al. 2002b). 
Figure 5. Domain structure of human HIF-1 HIF-1 belong to the bHLH and PAS 
protein family. It contains an ODDD that mediates oxygen-regulated stability through the 
hydroxylation of two proline (P) residues and the acetylation of a lysine (K). HIF-1also 
contains two transaction domains (C-TAD and N-TAD). The total number of amino acids 
of HIF-1 is marked at the end of the domain structure. (Ke and Costa 2006) 
Under normoxia, two proline residues Pro402 and Pro564 within ODD domain of HIF-1 are 
hydroxylated by prolyl hydroxylase (PHD) to promote the interaction of HIF-1 with pVHL (von 
Hippel-lindau tumor suppressor) which is a part of ubiquitin ligase complex to tag HIF-1 with 
ubiquitin, leading to HIF-1 degradation by 26S proteasome (Masson and Ratcliffe 2003; 
Masson, et al. 2001; Srinivas, et al. 1999). The lysine residue 532 (Lys532) located in the 
ODDD domain of HIF-1is acetylated by an acetyl-transferase called arrest-defective-1 
(ARD1), which facilitates the binding of HIF-1 with pVHL, and thus destabilizes HIF-
1(Jeong, et al. 2002) The hydroxylation of an asparagine residue N803 in the C-TAD by the 
factor inhibiting HIF-1 (FIH-1) prevents the association of HIF-1 with CBP/p300 which results 
in transcriptional inactivity (Hewitson, et al. 2002; Lando, et al. 2002b; Sang, et al. 2002). The 
PHD and FIH-1, regarded as oxygen sensors, are 2-oxoglutarate (2-OG)-dependent 
diooxygenases requiring oxygen for hydroxylation as well as Fe2+ and ascorbate as cofactors. 
Their activity to impair HIF-1stabilization and transcriptional activity, respectively, is known 
to depend on the oxygen concentration (Epstein, et al. 2001; Jewell, et al. 2001; Lando, et al. 
2002a; Lando, et al. 2002b; Schofield and Zhang 1999). The ARD1 is not influenced by 
oxygen, but the mRNA and protein levels of ARD1 were higher in normoxia than in hypoxia, 
causing more acetylated HIF-1 in normoxia (Jeong, et al. 2002). Under hypoxia, PHD and 
FIH-1 lose the activity of mediating hydroxylation of HIF-1 due to lack of oxygen, thus non-
hydroxylated HIF-1 is stabilized without pVHL binding and CBP/p300 recruitment is allowed. 
Then, stabilized HIF-1 translocates into the nucleus and binds to HIF-1, resulting in gene 
transcription (Figure 6) (Ke and Costa 2006). In addition, recently sumoylation of HIF-1 has 
been identified as another posttranslational modification to stabilize HIF-1 against 
degradation (Bae, et al. 2004; Carbia-Nagashima, et al. 2007; Shao, et al. 2004).  
Besides hypoxia, HIF-1 is also regulated by cytokines, growth factors, environmental stimuli, 
and other signaling molecules under normoxia (Feldser, et al. 1999; Gorlach, et al. 2001; 
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Haddad and Land 2001; Hellwig-Burgel, et al. 1999; Ke and Costa 2006; Li, et al. 2004; 
Richard, et al. 2000; Salnikow, et al. 2000; Stiehl, et al. 2002). HIF-1 transactivation or 
synthesis is also shown to be induced by activation of mitogen-activated protein kinase 
(MAPK) or the phosphatidylinositol 3-kinase (PI3K) signaling pathways (Li, et al. 2004; Zelzer, 
et al. 1998). 
HIF-1, inducing a large number of target gene transcriptions, plays a general role in multiple 
physiological responses to hypoxia, such as erythropoiesis and glycolysis, which quickly 
counteract oxygen deficiency, and angiogenesis, which provides a long-term solution (Ke and 
Costa 2006; Semenza 1998). Tumor growth leads to progressively hypoxic condition in the 
inner area as its size increases until enough blood vessels are built by tumors. Over-
expression of HIF-1 has been found in various human cancers such as breast, colon, 
pancreas, prostate, bladder, ovary, liver, kidney and brain, probably as a consequence of 
intratumoral hypoxia or genetic alteration, resulting in the subsequent induction of 
proangiogenic genes such as VEGF which is one the major target genes of HIF-1 (An, et al. 
2000; Berra, et al. 2000; Conway, et al. 2001; Harris 2000; Josko, et al. 2000; Talks, et al. 
2000; Zhong, et al. 1999).  HIF-1 also induces growth factors such as insulin-like growth 
factor-2 (IGF-2) and transforming growth factor- (TGF-), leading to cell proliferation and 
survival in hypoxia (Feldser, et al. 1999; Krishnamachary, et al. 2003). Paradoxically, HIF-1 
has been shown to promote apoptosis induced by hypoxia (Carmeliet, et al. 1998). For 
example, proapoptotic protein Bcl-2/adenovirusEIB19-KDa interacting protein 3 (BNip3) and 
its homolog Nip3-like protein X (NIX) have shown to be up-regulated in a HIF-dependent 
manner (Bruick 2000).  
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Figure 6. Oxygen-dependent regulation of HIF-1 stabilization and transactivation. In 
normoxia (left), two proline residues of HIF-1 (P402 and P564) and asparagine (N803) 
are hydroxylated by PHDs and FIH-1, respectively, in an O2, 2-OG, and Fe
2+
-dependent 
manner. Hydroxylated HIF-1 proteins bind to the E3 ubiquitin ligase VHL complex, 
leading to its degradation by the proteasome. Acetylation of lysine (K532) by ARD1 favors 
the interaction of HIF-1 with VHL. Hydroxylated N803 blocks the recruitment of 
transcriptional coactivator CBP/p300. In hypoxia (right), the activities of PHDs and FIH-1 
are inhibited due to lack of O2, resulted in no proline and asparagine hydroxylation. 
Therefore, there is no VHL binding and HIF-1 is stabilized. Stabilized HIF-1 proteins 
translocate to the nucleus and bind to HIF-1. HIF-1 may bind preferentially to the 
MAPK-induced phosphorylated form of HIF-1. Nonhydroxylated N803 of HIF-1 allows 
CBP/p300 recruitment to the target genes, resulting in gene transcription. In addition, the 
expression of ARD1 is decreased under hypoxia, causing less acetylated HIF-1. (Ke and 
Costa 2006) 
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1.8 VEGF 
VEGF (also known as VEGF-A) belongs to the VEGF family which also includes VGEF-B, C, 
D, E, and placental growth factor (PIGF) (Achen, et al. 1998; Joukov, et al. 1996; Lee, et al. 
1996; Lyttle, et al. 1994; Maglione, et al. 1991; Maglione, et al. 1993; Orlandini, et al. 1996). 
VEGF is a key regulator of angiogenesis, while VEGF-B is required for normal heart function 
in adults but is not required for cardiovascular development or for angiogenesis, and VEGF-C 
and VEGF-D participate in embryonic lymphangiogenesis (Ferrara 2004; Karkkainen, et al. 
2004; Roskoski 2007). VEGF-E is encoded by the Orf parapoxvirus, supporting the 
angiogenesis associated with parapoxvirus-infected lesion (Meyer, et al. 1999). PIGF 
enhances VEGF signaling (Carmeliet, et al. 2001).  
Alternative exon splicing of VEGF gene generates four different isoforms of VEGF: VEGF121, 
VEGF165, VEGF189, and VEGF206, having 121, 165, 189, and 206 amino acids, respectively, 
after signal sequence cleavage (Houck, et al. 1991; Tischer, et al. 1991).  VEGF165, which is 
the predominant isoform, is a heparin-binding homodimeric glycoprotein of 45 KD, and it is 
secreted but a significant fraction remains bound to the cell surface and extracellular matrix 
(Ferrara and Henzel 1989; Houck, et al. 1992; Park, et al. 1993). VEGF121, which does not 
bind heparin, is a freely diffusible protein (Houck, et al. 1992; Park, et al. 1993). VEGF183 and 
VEGF206 have high affinity with heparin, and they are almost completely sequestered in the 
ECM (extracellular matrix), but may be released in a diffusible form by heparin or heparinase, 
which displaces them from their binding to heparin-like moieties, or by plasmin cleavage at the 
COOH terminus, which generates a bioactive fragment containing the first 110 NH2-terminal 
amino acids (Houck, et al. 1992; Park, et al. 1993). VEGF interacts with two highly related 
receptor tyrosine kinases (RTKs), VGEFR-1 and VEGFR-2; while the co-receptor neuropilin 1 
(NP1) enhances the binding of VEGF165 to VEGFR-2 and VEGF165-mediated chemotaxis (de 
Vries, et al. 1992; Soker, et al. 1998; Terman, et al. 1992). 
VEGF has the ability to promote growth and survival of vascular endothelial cells (ECs) 
derived from arteries, veins and lymph vessels (Ferrara and Davis-Smyth 1997), and also has 
mitogenic effects on certain non-EC types such as retinal pigment epithelial cells, pancreatic 
duct cells and Schwann cells (Compernolle, et al. 2002; Guerrin, et al. 1995; Oberg-Welsh, et 
al. 1997; Sondell, et al. 1999). VEGF also has effects on the bone marrow-derived cells and 
hematopoiesis. It promotes monocyte chemotaxis and controls hematopoietic stem cell 
survival during hematopoietic repopulation (Clauss, et al. 1990; Gerber, et al. 2002). The 
potential role of VEGF as a neuronal protective factor has been demonstrated by recent 
studies in amyotrophic lateral sclerosis (Lambrechts, et al. 2003). Moreover, VEGF induces 
vascular permeability, underlining its important role in inflammation (Dvorak, et al. 1995; 
Senger, et al. 1983).  
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VEGF mRNA transcription is induced by hypoxia in various pathophysiological circumstances 
(Dor, et al. 2001). The VEGF gene has a single hypoxia response element (HRE) in the 
promoter, which is the HIF-1 binding site (Madan and Curtin 1993). Besides oxygen tension, 
several major growth factors and inflammatory cytokines, including epidermal growth factor, 
TGF-, TGF-, IGF-1, FGF, keratinocyte growth factor, IL-1 and IL-6, also up-regulate VEGF 
expression, indicating that VEGF release is under regulation of the autocrine or paracrine 
factors together with local hypoxia in the microenvironment (Ferrara and Davis-Smyth 1997; 
Neufeld, et al. 1999). Oncogenic mutations or amplification of ras proto-oncogene over-
activate the Raf-Mek-Erk MAP kinase cascade, leading to increased VGEF expression 
(Grugel, et al. 1995; Okada, et al. 1998).  
VEGF plays an essential role in both physiological angiogenesis (such as angiogenesis during 
embryonic and postnatal development, skeletal growth, endochondral bone formation, and 
angiogenesis in endocrine glands) and pathological angiogenesis (such as angiogenesis in 
solid tumors, haematological malignancies, intraocular neovascular syndromes, inflammatory 
disorders and brain edema, and diseases of the female reproductive system) (Ferrara 2004). 
As mentioned above, tumor growth has the requirement for angiogenesis, and therefore, 
VEGF is identified as an essential factor for tumor angiogenesis. It has been shown by in situ 
hybridization studies that VEGF mRNA is significantly up-regulated in the vast majority of 
human tumors, such as carcinoma of the lung, breast, gastrointestinal tract, kidney, bladder, 
ovary, endometrium, and several intracranial tumors including glioblastoma multiforme and 
sporadic, as well as VHL syndrome-associated, capillary hemangioblastomas (Ferrara 2004). 
VEGFR-1 and VEGFR-2 are expressed in endothelial cells, indicating that VEGF released by 
tumor cells may influence the endothelial cells nearby in a paracrine manner (Roskoski 2007). 
VEGF is also expressed in pituitary adenomas, although it has been shown to be generally 
less intense than in normal pituitary by immunohistochemistry (Lloyd, et al. 1999). Pituitary 
carcinomas show relatively increased VEGF expression compared with adenomas, 
suggesting an up-regulation of VEGF expression during pituitary tumor progression (Lloyd, et 
al. 1999). Interestingly, VEGF-A is not only acting as an angiogenic but also as a growth factor 
on pituitary adenomas through differently expressed VEGF receptors in tumor and vessel cells 
of pituitary tumors (Onofri, et al. 2006). Monoclonal anti-VEGF antibodies suppress growth of 
various transplanted tumor cell lines in nude mice (Kim, et al. 1993). Therapeutic trials using 
anti-VEGF antibodies, genetically engineered VEGF-binding proteins and VEGF receptor 
protein-tyrosine kinase inhibitors have been performed, and VEGF pathway inhibitors are now 
being explored in combination with chemotherapy for many types of solid tumor (Roskoski 
2007).  
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2 Aim of this study 
RSUME, a novel protein, was shown to enhance HIF-1 stabilization and transcriptional 
activity in monkey kidney cell line COS-7, and a large number of studies have demonstrated 
that HIF-1and its target VEGF play essential roles in growth and progression of a wide 
variety of solid tumors by promoting tumor angiogenesis. However, only few reports focus on 
the role of HIF-1 and VEGF in slowly growing and poorly vascularized pituitary adenomas, 
and whether RSUME is implicated in pituitary adenoma angiogenesis and development is 
completely unclear.  
The aim of this study is to investigate the expression and regulation of HIF-1, VEGF and 
RSUME in pituitary adenomas and also to explore novel additional functions of RSUME in 
pathogenesis of pituitary adenomas.  
In order to achieve these goals, experiments were carried out with human pituitary adenomas 
and mouse pituitary cell lines. HIF-1, VEGF and RSUME were examined at RNA level by 
quantitative real-time PCR in human pituitary adenoma tissues. HIF-1, VEGF protein 
expression and RSUME mRNA expression were measured by western blot, ELISA and 
quantitative real-time PCR respectively after hypoxia-mimicking stimulation in mouse pituitary 
adenoma cell lines and primary human pituitary adenoma cell cultures. HIF-1 translocation 
after hypoxia mimicking treatment was demonstrated by immunofluorescence studies. 
RSUME knockdown was performed by siRNA technology to clarify its relationship with HIF-1 
and VEGF in pituitary cell lines and primary cell cultures. The role of RSUME in pituitary cell 
proliferation and survival was noticed in the experiments with RSUME knockdown and 
analyzed by WST-1 assay, cell number counting, cell death ELISA, and immunofluorescence 
studies on pro-apoptotic protein cleaved caspase-3.  
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3 Materials and methods 
3.1 Regents 
Product  Company  
Acridine orange  Sigma (St. Louis. MO, USA)  
Ammonium persulfate  Sigma (St. Louis. MO, USA)  
Ampuwa water  Fresenius (Germany)  
Alexa Fluor 594 Invitrogen (Carlsbad, CA, USA) 
Beta-mercaptoethanol  MERCK (Darmstadt, Germany)  
Biomax MR films  Kodak (Stuttgart, Germany)  
BLOCK-iTTM Alexa Fluor
® red fluorescent 
oligo 
Invitrogen Corp. (Paisley, UK) 
Bovine serum albumin (BSA)  Invitrogen Corp. (Paisley, UK)  
Protein assay Dye Reagent  Biorad (Munich, Germany)  
Chloroform  Sigma (St. Louis. MO, USA)  
Collagenase  
Worthington Biochemical Corp. 
(Lakewood, NJ, USA)  
Culture slides BD biosciences (California, USA) 
Developer solution  Kodak (Stuttgart, Germany)  
Diethyl-pyrocarbonate (DEPC)  Sigma (St. Louis. MO, USA)  
Dimethyl sulfoxide (DMSO)  Sigma (St. Louis. MO, USA)  
Dithiothreitol (DTT)  Sigma (St. Louis. MO, USA)  
DNase I Invitrogen Corp (Paisley, UK)  
dNTP Mix  MBI Fermentas (Vilnius, Lithouania)  
Dulbecco’s modified Eagle medium 
(DMEM)  
Invitrogen Corp (Paisley, UK)  
Ethylenediaminotetraacetic acid (EDTA)  MERCK (Darmstadt, Germany)  
Ethidium bromide  Sigma (St. Louis. MO, USA)  
Fetal calf serum  Gibco (Karlsruhe, Germany)  
Fixer solution  Kodak (Stuttgart, Germany)  
Guanidine thiocyanate 
Fluka Chemie AG (Buchs, 
Switzerland) 
Hexanucleotide Mix  Roche (Mannheim, Germany)  
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Hydrochloric acid  MERCK (Darmstadt, Germany)  
Hyperfilm ECL 
Amersham Biosciences (Uppsala, 
Sweden) 
Isopropanol  Sigma (St. Louis. MO, USA)  
KCl MERCK (Darmstadt, Germany) 
KH2PO4 MERCK (Darmstadt, Germany) 
LipofectamineTM 2000  Invitrogen Corp (Paisle, UK) 
L-Glutamine  Biochrom AG (Berlin, Germany)  
Loading Buffer 4× Roth (Karlsruhe, Germany) 
Lumi-Light Western Blotting Substrate  Roche (Mannheim, Germany)  
Magnesium chloride  MERCK (Darmstadt, Germany)  
Marker 1kb Plus  Life Technologies (Paisley, UK)  
MEM-Vitamins  Biochrom (Berlin, Germany)  
Milk powder  Roth (Karlsruhe, Germany)  
Nitrocellulose membrane Hybond-ECL  
Amersham Biosciences (Uppsala, 
Sweden)  
Paraformaldehyde (PFA)  MERCK (Darmstadt, Germany)  
Partricin Biochrom (Berlin, Germany) 
PBS  
Gibco/invitrogen (Carlsbad, CA, 
USA)  
Penicillin+Streptavidine mix  Biochrom AG (Berlin, Germany)  
Cultrex
® 
Poly-L-Lysine 
R&D Systems (Wiesbaden, 
Germany) 
Ponceau S solution Sigma (St. Louis, Mo, USA) 
Phenol  Roth (Karlsruhe, Germany)  
Phosphate based buffer  
PBS  
Life Technologies (Paisley, UK)  
Polyacrylamide  Invitrogen Corp (Paisle, UK)  
ProLong gold anti-fade reagent with DAPI Invitrogen (Carlsbad, CA, USA) 
Goat serum Sigma (St. Louis, Mo, USA) 
RNAsin (RNase inhibitor)  Promega Corp. (Madison, WI, USA)  
Rneasy Mini kit  QIAGEN (Hilden, Germany)  
Reverse transcriptase  
(SuperScript II TM )  
Invitrogen (Carlsbad, CA, USA)  
Semi-dry blotter Invitrogen (Carlsbad, CA, USA) 
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siRNA against RSUME MWG Biotech (Ebersberg, Germany) 
Sodium acetate dihydrate  MERCK (Darmstadt, Germany)  
Sodium acetate trihydrate  MERCK (Darmstadt, Germany)  
Sodium chloride (NaCl)  Roth (Karlsruhe, Germany)  
Sodium citrate dihydrate  MERCK (Darmstadt, Germany)  
Sodium dihydrogen phosphate mono-
hydrate  
(NaH2PO4-H2O)  
MERCK (Darmstadt, Germany)  
Sodium hydrogen phosphate dihydrate 
(Na2HPO4-2H2O)  
MERCK (Darmstadt, Germany)  
Sodium peroxyde (NaOH)  MERCK (Darmstadt, Germany)  
Taq DNA polymerase  MBI Fermentas  
TEMED  Sigma (St. Louis, Mo, USA)  
Transferrin Sigma (St. Louis, Mo, USA) 
Triiodothyronine Henning (Berlin, Germany) 
Tris-Glycine 10% gel  Anamed (Darmstadt, Germany)  
Tris pure  
ICN Pharmaceuticals (Aurora, OH, 
USA)  
Triton X-100  Roth (Karlsruhe, Germany)  
Trizol Invitrogen (Carlsbad, CA, USA) 
Trypsin  Sigma (St. Louis, Mo, USA)  
Tween 20  Sigma (St. Louis, Mo, USA)  
WST-1 reagent Roche (Mannheim, Germany) 
3.2 Solutions 
Acridin orange/ ethidium 
bromide solution 
Acridinorange: 50 µl 200 mg/l 
Ethidiumbromid: 50 µl 10 mg/l  
PBS: 900 µl 
Collagenase Mix  
1000 U/ml  
Collagenase : 4g/ 100ml solution  
Trypsin inhibitor : 10 mg/ 100ml solution  
Hyaluronidase : 100 mg/ 100ml solution  
BSA : 400 mg/ 100ml solution  
DNase : 500 μl/ 100ml solution  
DEPC water  
200 μl DEPC/l deionized water  
Leave under the fume hood overnight  
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Autoclave  
HDB buffer  
Hepes: 5,95 g/l  
NaCl : 8 g/l  
KCl: 0,37 g/l  
Na2HPO4.H2O: 0,12 g/l  
Glucose: 1,982 g/l  
Amphotericine B 25μg/ml: 10 ml  
Penicillin/Streptomycin 105U/l : 10 ml  
Adjust pH to 7,3 with NaOH  
Store at +4°C  
4% Paraformaldehyde (PFA)  
paraformaldehyde: 4 g/100 ml  
Sodium phosphate buffer: 20 ml/100ml  
Ampuwa water: 80 ml  
Add 1M NaOH to pH 7.4  
Heat at 56°C to dissolve  
Filter and cool before usage  
Store at +4°C for maximum 2 days  
Phosphate based buffer (PBS)  
NaCl: 8 g/l  
KCl: 0.2 g/l  
Na2HPO4.2H2O: 1.44 g/l  
KH2PO4: 0.2 g/l  
Adjust to pH 7.4  
RIPA buffer 
50 mM Tris pH 8.0 
150 mM NaCl 
1% NP40 
0.5% Sodium Deoxicholate 
0.1% SDS 
1% Triton X-100 
10 x Running buffer for protein 
electrophoresis 
Tris-base: 30.3 g/L 
Glycine: 144.2 g/L 
SDS: 10 g/L 
Adjust pH to 8.3 
2M Sodium acetate  
Sodium acetate trihydrate: 27.2 g/ 100ml  
DEPC: 20 μl  
Add acetic acid to pH 4.0  
Leave at room temperature overnight and the 
next day autoclave  
Solution D 
4 M Guanidium thiocyanate: 250 g/337 ml 
0.75 M sodium citrate pH 7.0 : 17.6 ml/337 ml 
10% Sarcosyl: 26.4 ml/337 ml 
dissolve in 293 ml DEPC 
To complete the medium add: 
180 µl beta-mercaptoethanol/25 ml solution just 
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before use 
Transfer buffer for semi-dry 
blotting 
39 mM Glycine 
48 mM Tris-Cl 
0.037% SDS 
10% Methanol 
10x Tris borate EDTA buffer 
(TBE)  
Boric acid (H3BO3): 61.83 g/l  
EDTA: 37.2 g/l  
Tris pure: 30.03 g/l  
Adjust to pH 8.0  
Tris-based buffer (TBS)  
Tris pure: 2.42 g/l  
NaCl: 8 g/l  
Adjust to pH 7.6  
3.3 Human pituitary and pituitary adenoma tissues  
This study was performed after approval of the local ethics committee (Ethics Grant No. 141-
07) and in the case of pituitary adenomas, informed written consent was received from each 
patient.  
3.3.1 Tissues used for investigation of HIF-1, VEGF and RSUME mRNA expression  
Normal human pituitaries (n=3) were obtained from autopsies, performed within 12 h after 
accidentally occurred death of 3 healthy persons: 2 males (age 67 and 47) and 1 female (age 
37). The tumor tissues received after transsphenoidal surgery from 31 patients: 13 males and 
18 females with 47.9±17.8 average age (range 26-80 years), classified according to clinical 
presentation in somatotrophinomas (n=6), corticotrophinomas (n=6), non-functioning 
adenomas (n=8), prolactinomas (n=7) and thyrotrophinomas (n=4) were shock frozen as soon 
as possible, stored at -80°C and later used for RT-PCR. All the tumors were benign and tumor 
grade was determined according to a modified Hardy´s classification (Boggild, et al. 1994) 
following the medical reports after nuclear magnetic resonance and after surgery: 1 grade I, 7 
grade II, 18 grade III cases were identified, and 5 cases couldn’t be identified from clinical 
data offered by neurosurgeons (Table 4). In patients pre-treated with somatostatin analogues 
or dopamine agonists, medication was stopped at least 1 week prior to surgery. All the tumor 
tissues were received within 12~16 hours after surgery. 
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Table 4. The clinical characteristics of the normal and 
adenomatous pituitary tissues included in this study. 
Tissue Gender Age Grade 
NP1 M 67 - 
NP2 M 46 - 
NP3 F 37 - 
CUSH1 F 46 II 
CUSH2 F 67 - 
CUSH3 M 37 III 
CUSH4 F 27 III 
CUSH5 F 64 - 
CUSH6 F 45 I 
NFPA1 M 65 II 
NFPA2 M 75 II 
NFPA3 F 40 III 
NFPA4 F 77 III 
NFPA5 F 70 II 
NFPA6 F 30 - 
NFPA7 M 54 III 
NFPA8 F 66 III 
ACRO1 F 34 II 
ACRO2 F 80 II 
ACRO3 F 27 III 
ACRO4 F 41 III 
ACRO5 M 36 III 
ACRO6 F 77 - 
TSH1 F 29 III 
TSH2 F 55 II 
TSH3 F 32 III 
TSH4 M 53 III 
PROL1 M 40 - 
PROL2 M 31 III 
PROL3 M 64 III 
PROL4 F 28 III 
PROL5 M 30 III 
PROL6 M 40 III 
PROL7 M 26 III 
NP, normal pituitary; CUSH, corticotrophinomas; NFPA, non-
functioning adenomas; ACRO, somatotrophinomas; TSH, 
thyrotrophinomas; PROL, prolactinomas; “ - “: no data.  
3.3.2 Tissues used for primary cell culture 
Human pituitary adenomas obtained from 36 patients were used for primary cell culture. For 
investigation of HIF-1 expression under hypoxia-mimicking conditions, 8 human pituitary 
adenomas (5 non-functioning, 2 somatotroph, and 1 lactotroph) were used. For investigation 
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of VEGF expression under hypoxia-mimicking conditions, 17 human pituitary adenomas (11 
non-functioning, 3 somatotroph, 2 lactotroph, and 1 cortocotroph) were used. For investigation 
of RSUME mRNA expression under hypoxia-mimicking conditions, 3 human pituitary 
adenomas (2 non-functioning and 1 somatotroph) were used. For investigation of effect on 
RSUME knockdown, 8 human pituitary adenomas (6 non-functioning, 1 somatotroph, and 1 
corticotroph) were used. All the tumor tissues were received within 12~16 hours after surgery 
and were cultivated as soon as possible. Due to the limited amount of human pituitary tumor 
tissue available, not all the experiments could be done in parallel in primary human pituitary 
tumor cells.       
3.4 RNA isolation 
RNA was isolated from normal human pituitaries and from human pituitary adenomas using 
the guanidium isothiocyanate protocol. The tissue piece was first homogenized in 800 μl of 
solution D supplemented with −mercaptoethanol, using the Ultra-TURRAX T8 (IKA 
Labortechnic, Germany) tissue homogenizer.  
Guanidium isothiocyanate and -mercaptoethanol inhibit the RNase action activated by cell 
disruption, preventing in this way RNA degradation. 80 μl of sodium acetate 2 M pH 4.0 were 
added afterwards to precipitate RNA, followed by 800 μl of saturated phenol and 160 μl of a 
choloroform-isoamyl alcohol (49:1) solution. After 15 minutes incubation on ice the samples 
were centrifuged at 13000 rpm for 20 minutes at 4°C; this step led to the formation of two 
phases, the upper one containing RNA and the lower one containing DNA and proteins. The 
upper phase was then transferred to a new tube together with the same volume of ice-cold 
isopropanol. Incubation of the sample at –20°C at least for 2 hours was necessary for RNA 
precipitation. After centrifugation of the sample at 13000 rpm for 10 minutes at 4°C, the 
supernatant was discarded and the pellet was washed with ice-cold ethanol 70%. After 10 
minutes centrifugation at 13000 rpm the supernatant was again discarded and the pellet left to 
dry at room temperature and then dissolved in an appropriate amount of DEPC-treated water.  
RNA extraction from pituitary adenoma cell lines (TtT/GF and AtT-20) and primary human 
pituitary adenoma cell cultures was performed with TRIzol
®
 Reagent according to the 
manufacturer’s instruction.  
The samples absorbance was measured with a photometer. The lack of DNA contamination 
was assessed performing a PCR reaction for a housekeeping gene -Actin, using the RNA 
sample: if no DNA contamination is present, no band is visible after loading the PCR product 
on an ethidium bromide gel (as described below). If DNA contamination was detected, RNA 
purification was performed with DNase I. 
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3.5 Reverse Transcriptase- Polymerase Chain Reaction  
Reverse transcription was performed by incubating 1 µg of total RNA with 1 μl of dNTP mix 2 
mM, 2 μl of 62.5 U/ml random primers (Hexanucleotide mix), 2 μl of dithiothreitol (DTT) 10 mM, 
1 μl of 200 U reverse transcriptase (SuperScript II), 4 μl of 5x first strand buffer and DEPC-
water to get a final volume of 20 μl, for 1 hour at 45°C. Reaction was stopped by boiling the 
samples at 95°C for 5 minutes.  
For semi-quantitative RT-PCR, 1 μl of cDNA samples obtained from TtT/GF and AtT20 cells 
were used for PCR reaction with primers specific for mouse RSUME, mouse VEGF, mouse -
Actin, human RSUME and human -Actin (Table 5). The cDNA samples were incubated with 
1.5 μl 10x PCR buffer, 0.9 μl MgCl2 25 mM, 1.5 μl dNTP mix 2mM, 0.5 μl amplification primer 
sense 10 pmol/μl, 0.5 μl amplification primer anti-sense 10 pmol/μl, 0.15 μl Thermus aquaticus 
(Taq) DNA polymerase and 8.95 μl autoclaved distilled water. The PCR reaction consisted of 
35 cycles each containing the following steps: denaturation at 94° C for 1 min, annealing at 58° 
C for 30 sec and finally elongation of the PCR fragment at 72° C for 1 min. 
The amplified fragments were electrophoresed in ethidium bromide agarose gel 1 - 1,5% 
according to the size of the product (1% for 500- 1100 bp fragments, 1,5% for 200- 500 bp 
fragments), in 1 X TBE buffer for 15-20 minutes at 80 V and then visualized under UV light. 
The 1 kb Plus DNA Ladder marker was used to determine the fragments size. 
Quantitative real time RT-PCR was performed with cDNA samples of TtT/GF, AtT-20 and 
primary human pituitary tumor cells as templates. The amplification reactions of 35 cycles 
were carried out with specific primers for human HIF-1, human VEGF, human RSUME, 
human -Actin, mouse RSUME, and mouse -Actin (Table 5). Absolute Blue QPCR SYBR 
Green Mix (Thermo Scientific) was used following the manufacturer’s instructions. PCR 
amplifications were performed in a MiniOpticon Real-Time PCR Detection System (Bio-Rad, 
Munich, Germany), and the data were analyzed with CFX Manager Software for MiniOpticon 
(version 1.5, Bio-Rad). For each sample, the gene copy number was normalized by the 
amount of -Actin. All experiments were carried out in triplicates. 
Each sequence of the primers was checked with the NCBI BLAST program in order to exclude 
eventual annealing with other genes different from the ones studied. All primers were 
synthesized by MWG Biotech, reconstituted with sterile distilled water to a concentration of 
100 μM and stored at -20 ° C.  
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Table 5. Primers used for RT-PCR 
Target Sequence (5’-3’) 
Tm 
(° C) 
Fragment 
(bp) 
Human HIF-1 
Sense: CAT AGA ACA GAC AGA AAA ATC TCA TCC 
Anti-sense: TTA ACT TGA TCC AAA GCT CTG AGT AAT 
58 450 
Human VEGF 
Sense: CAG ATT ATG CGG ATC AAA CCT 
Anti-sense: CAA ATG CTT TCT CCG CTC TGA 
58 148 
Human RSUME 
Sense: TAC CTG GTA TCT CGA TTA ACT CTG AAC 
Anti-sense: TCA GTA TTA TTT TAC CCA TGA ACA TCA 
58 300 
Human -Actin 
Sense: ACG GGG TCA CCC ACA CTG TGC 
Anti-sense: CTA GAA GCA TTT GCG GTG GAC GAT G 
58 660 
Mouse VEGF 
Sense: TCT ACC AGC GAA GCT ACT GCC 
Anti-sense: TTA CAC GTC TGC GGA TCT TG 
58 349 
Mouse RSUME 
Sense: GAC TCA AGT GGA AAG AAA TGC AA 
Anti-sense: GGA AAT CAA AAC CAG GCT GT 
58 199 
Mouse -Actin 
Sense: AGT ATC CAT GAA ATA AGT GGT TAC AGG 
Anti-sense: CAC TTT TAT TGG TCT CAA GTC AVT GTA 
58 300 
 
3.6 Cell culture and stimulation experiments 
Folliculostellate TtT/GF and corticotroph AtT20 mouse pituitary tumor cells were grown in 
DMEM supplemented with 10% FCS, 2 nmol/l glutamine, 0.5 mg/l partricin, and 105 U/l 
penicillin-streptomycin at 37°C and 5% CO2.  
For primary human pituitary tumor cell culture, adenoma tissue was cultivated as below. The 
tissue was washed with HDB buffer. Sliced fragments were enzymatically dispersed in a buffer 
containing 4 g/l collagenase, 10 mg/l DNase II, 0.1 g/l soybean trypsin inhibitor, and 1 g/l 
hyaluronidase (37°C, approximately 45 minutes). Dispersed cells were centrifuged and 
resuspended in tumor medium (DMEM supplemented with 2 mM essential vitamins, 40U/l 
insulin, 20 ng/l natrium selenate, 5 mg/l transferrin, 30 pM triiodothyronine (T3), 10% fetal calf 
serum, 2 mmol/l L-glutamine, 0.5 mg/l partricin and 105 U/ml penicillin-streptomycin). Cell 
viability was determined by fluorescence microscopy after staining with acridin orange and 
ethidium bromide. Acridin orange enters the membranes of normal cells, yielding green 
fluorescence in viable cells. Ethidium bromide does not pass the healthy cell membrane and 
enters only in dead cells with damaged membranes, yielding a red fluorescence. Cell viability 
of pituitary cells was determined as the percentage of green cells in the total number of cells 
(counted in a neubauer chamber). Cells were distributed in 48-well plates or 24-well plates 
and incubated at 37°C under 5 % CO2. The human adenoma cells attached to the plastic wells 
within 24 h and were then used for stimulation experiments. 
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CoCl2 was dissolved in distilled water as a stock solution of 200 mM, and was diluted in cell 
culture medium to stimulate pituitary tumor cells for various time periods and at different 
concentrations as indicated.  
3.7 Cell counting 
In this study, cell number was counted with the neubauer chamber before seeding plates or 
petri dishes. After trypsinizing and washing the cells, the cells were resuspended according to 
the size of pellet in 5ml, 10ml or 20 ml Medium. 50 µl cell suspension and 50 µl color solution 
(mixture of 50 µl 200mg/l Acridinorange, 50 µl 10 mg/l Ethidiumbromid and 900 µl PBS) were 
mixed. The coverslip was placed over the counting chambers and the diluted cell suspension 
was loaded into the counting chambers. Approximately 10 µl was required. The entire volume 
of the chamber was filled, but not overfilled. The cells were viewed under a microscope at 
100x magnification. The cells were visible above the grid of the counting chamber (Figure 7). 
The number of viable cells (cells with green color under UV light) was determined overlying 4 
x 1 mm2 areas of the counting chamber (labeled A-D in Figure 7). The cell concentration was 
calculated: firstly, the total cells counted in 4 mm2 was divided by 4; secondly, the average of 
cell number in 1 mm2 area was divided by the dilution factor 1/2; thirdly, the cell number of 1 
mm2 area was divided by 10-4 ml, the volume of 1 mm2 area; finally, the cell number of 1 ml 
medium was obtained. 
Figure 7. The neubauer chamber for cell counting. 
3.8 Transfection of siRNA against RSUME 
RNA interference (RNAi) is a gene silencing system in eukaryotic cells, by which double-
stranded RNA (dsRNA) triggers the destruction of mRNA with sequence complementarity. 
A B 
C D 
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RNAi is initiated by the conversion of dsRNA into 21~23 nt fragments known as small 
interfering RNAs (siRNAs) by the multidomain RNase III enzyme (Dicer). These siRNAs are 
then incorporated into a second enzyme complex, the RNA-induced silencing complex (RISC), 
in an ATP-dependent step or series of steps during which the siRNA duplex is unwound into 
single strands. The resulting single stranded siRNA guides the RISC to recognize and cleave 
the target RNA complementary to the siRNA sequence (Figure 8) (Schwarz, et al. 2002). 
Nowadays, siRNA is applied in biology research. Designed siRNA is transfected into 
mammalian cells to suppress expression of specific genes, which has become a useful tool to 
explore the function of target genes. 
Figure 8. The siRNA pathway. Long double-stranded RNA (dsRNA) is digested by Dicer 
in an ATP-dependant way. Then siRNAs are uptaken by RISC. ATPs are hydrolysed to 
help unwind of siRNA but the incorporation is ATP independent. The single-stranded 
antisense strand help RISC to find the target mRNA, and the mRNA is cleaved. (Schwarz, 
et al. 2002) 
3.8.1 Transfection of siRNA against mouse RSUME in pituitary cell lines 
TtT/GF and AtT20 cells were seeded in plates with antibiotics-free culture medium. After 
overnight growing, 100 nM siRNA against mouse RSUME (5’- GGA CTT GTG GGT GAG GAT 
G-3’, supplied by Prof. Arzt, FCEN-Universidad de Buenos Aires, Argentina) was transfected 
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into cells with lipofectamineTM 2000 (Invitrogen, Karlsruhe, Germany) to suppress endogenous 
RSUME expression. 100 nM scrambled siRNA (Scramble II, MWG Biotech, Ebersberg, 
Germany) was used as a control. The time periods of transfection are described in results. 
3.8.2 Transfection of siRNA against human RSUME in primary human pituitary 
adenoma cells 
Transfection of siRNA in primary human pituitary adenoma cells was established in 6 primary 
cell cultures of human non-functioning pituitary adenomas in this study. BLOCK-iTTM Alexa 
Fluor
® red fluorescent oligo (Invitrogen Corp, Paisley, UK) was used for determination of 
transfection efficiency. The BLOCK-iTTM Alexa Fluor
® red fluorescent oligo is Alexa Fluor 555-
labeled, double-stranded RNA (dsRNA) oligomer. It is designed for use in RNAi analysis to 
facilitate assessment and optimization of dsRNA oligonucleotides delivery into mammalian 
cells using cationic lipids (such as lipofectamineTM 2000). In this study, 10 nM, 20 nM, 50 nM 
or 100 nM fluorescent oligo was transfected with lipofectamineTM 2000 into primary human 
pituitary cells. 24 hours after transfection, primary cells were observed under fluorescence 
microscope with standard filter set for detection of Texas red (Carl Zeiss MicroImaging, 
Munich, Germany). Transfection efficiency was determined by counting the number of cells 
with red color in 100 cells. 
The optimized transfection conditions are described as follows. After dispersion of human 
pituitary adenomas, 200,000~250,000 adenoma cells/well were cultivated in poly-L-Lysine 
coated 24-well plates with 500 µl antibiotics-free tumor medium. After overnight incubation, for 
each well, 100 µl Opti-MEM I reduced serum medium containing 20 nM or 50 nM siRNA 
against human RSUME (5’- GGA TTT ATG GAT GCG GAT A-3’, supplied by Prof. Arzt, 
FCEN-Universidad de Buenos Aires, Argentina) and 1 µl lipofectamineTM 2000 was added to 
the cells to suppress endogenous RSUME expression. 100 nM scrambled siRNA (Scramble II, 
MWG Biotech, Ebersberg, Germany) was used as a control. The time periods of transfection 
are described in the results. 
3.9 Western blot analysis 
The western blot is a kind of immunoblot technique for detection of specific proteins in various 
samples, such as tissue homogenate or extract of cell cultures. The native or denatured 
proteins are firstly separated by molecular weight or 3D-structure, respectively, using gel 
electrophoresis, and then the proteins are transferred onto nitrocellulose or polyvinylidene 
fluoride membranes. For the two-step method, the primary antibody is applied to probe the 
target protein after blocking the membrane typically with bovine serum albumin (BSA) or non-
fat milk solution to avoid unspecific binding. Afterwards, the membrane is incubated with the 
Materials and methods 
40 
 
secondary antibody which binds to a species-specific binding site of the primary antibody. The 
secondary antibody is usually conjugated with a reporter enzyme such as horseradish 
peroxidase (HRP), which produces luminescence visualized on the film in proportion to the 
amount of target protein after reaction with chemiluminescent agent. 
In this study, after CoCl2 stimulation, the cells were washed with cold PBS, removed from the 
dish with a plastic scraper and the proteins were extracted breaking the cell membranes by 
pipetting up and down through a very small (insulin) syringe, in proteases inhibitor cocktail 
diluted 1:100 in RIPA buffer, working always on ice.  
The protein samples concentration was determined with Bradford dye assay (Bradford 1976). 
In the acidic environment of the reagent, protein binds to the coomassie dye. This results in a 
spectral shift from the reddish/brown form of the dye (absorbance maximum at 465 nm) to the 
blue form of the dye (absorbance maximum at 610 nm). The difference between the two forms 
of the dye is greatest at 595 nm, which therefore is the optimal wavelength to measure the 
blue color from the coomassie dye-protein complex. The linear standard curve was 
established by a serial concentration (0, 1, 2, 4, 6, 10, 15 µg/ml) of BSA/coomassie dye 
solution. The absorbance was measured by a spectrophotometer (Bio-rad, SmartSpecTMPlus). 
This standard curve is valid when the square of coefficient of determination value R2 ≥ 0.991; 
otherwise, the assay should be repeated. To determine the protein concentration of a test 
sample from absorbance, the standard curve was used to find the concentration of standard 
that would have the same absorbance as the sample. 
30 μg of each sample was separated by a pre-cast Tris-glycine gel (Anamed, Darmstadt, 
Germany) in an electrophoresis apparatus (Invitrogen). Then, the separated proteins were 
transferred on a nitrocellulose membrane (Hybond ECL) with Novex
®
 Semi-Dry Blotter 
(Invitrogen) through a electrophoresis procedure, in which the gel was on the negative side of 
the apparatus and the nitrocellulose membrane on the positive side, in this way the negative-
charged proteins are driven from the gel to the positive-charged membrane, in the same 
position. The membrane was then blocked in 5% non-fat milk solution (dissolved in TBS/0.1% 
tween) for 2 h. The blocked membrane was incubated with mouse monoclonal antibody 
against HIF-1 (diluted in 2.5% non-fat milk solution, 1:500, R&D Systems, Germany) or -
Actin (dilute in 2.5% non-fat milk solution, 1:10000, Milipore, USA) overnight at 4 °C. After 
washing three times with TBS/0.1% tween, the membrane was incubated with HRP-
conjugated anti-mouse antibody (diluted in 2.5% non-fat milk solution, 1:2000, Cell Signaling, 
USA) for 1 h. ECL system and hyperfilm (GE Health, Germany) were used for membrane 
visualization.  
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3.10 Immunofluorescence assay 
Immunocytochemistry was applied in cultured cells in this study. It is a common technique to 
assess the localization, distribution and expression level of target protein in situ, using a 
specific antibody, and this antibody-antigen interaction can be visualized by many methods 
under the conventional microscope, fluorescence microscope or confocal microscope. 
Immunofluorescence is a method widely used in immunocytochemistry to visualize the target 
proteins with fluorescent dye. As for the indirect immunofluorescence assay, the secondary 
antibody labeled with fluorescent dye is used to bind with the primary antibody which is 
against the antigen being probed for (Figure 9). The Alexa Fluor fluorescent dyes conjugated 
secondary antibodies are typically used, because the Alexa Fluor family has more robust 
fluorophores which are less prone to photobleaching. 
Figure 9. The principle of indirect fluorescence assay. The target antigen is 
recognized by the specific primary antibody which is recognized by the fluorescent labeled 
secondary antibody. The fluorescence is observed under fluorescence microscope or 
confocal microscope. 
The confocal microscope is popularly applied in life sciences, and it uses a kind of optical 
imaging technique which can increase micrograph contrast and reconstruct three dimensional 
images. With conventional microscopes, the fluorescence of the entire of specimen excited in 
the optical path is detected as background signal. In contrast, the confocal microscope uses 
point illumination and an aperture in front of fluorescence detector to eliminate out-of-focus 
signal, so only fluorescence very closed to the focal plane and in the sample depth direction 
can be detected, which results in higher image resolution than that of conventional 
fluorescence microscopes. However, scanning over a regular raster (i.e. a rectangular pattern 
Cell 
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of parallel scanning lines) in the specimen is required in 2D or 3D imaging, because only one 
point in the sample is illuminated at a time (Figure 10). 
Figure 10. The principal light pathways in confocal microscope. A laser provides the 
excitation light, and the laser light reflects off a beam splitter to get across the specimen. 
Afterwards, the fluorescence dyes in the specimen is emitted, then the emitted light 
passes through the beam splitter and is focused onto the aperture. The light passing 
trough the aperture is measured by the fluorescence detector. 
In this study, 24 hours after transfection with siRNA against RSUME and scramble siRNA in 6-
well plates, cells were split onto Falcon culture slides (BD biosciences), and stimulated with 
250 µM CoCl2 for 3 hours the next day. After treatment, cells were fixed in 4% 
paraformaldehyde for 5 minutes on ice, and then blocked in 5% goat serum with 0.1% (v/v) 
triton X-100 for 30 minutes at room temperature. Slides were incubated with mouse 
monoclonal anti-HIF-1 (1: 100, Novus Biologicals, USA), rabbit polyclonal anti-cleaved-
caspase-3 (1:200, Cell Signaling, USA) or rabbit polyclonal anti-VEGF (1:100, Abcam, USA) 
overnight at 4 °C, and then washed and incubated with Alexa Fluor
®
 594 goat anti-mouse 
antibody ((Invitrogen, Paisley, UK) or Alexa Fluor
®
 594 goat anti-rabbit antibody (Invitrogen, 
Paisley, UK) for 45 minutes at room temperature. ProLong
®
 Gold antifade reagent with DAPI 
(Invitrogen, Paisley, UK) was used for visualization of the cell nucleus. Images were obtained 
using a confocal microscope (FluoView™ FV1000, Olympus, Munich, Germany). The 
proportion of cells immunopositive for cleaved caspase-3 was determined by counting the 
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Aperture 
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Aperture 
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Lens 
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Out-of-focus-light rays 
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number of positive cells out of 100 cells in five different areas of each slice. Images were 
obtained using 10×, 20× or 60× objectives. 
3.11 Enzyme-Linked Immunosorbent Assay (ELISA) 
Figure 11. The procedure of sandwich ELISA. 
ELISA is a biochemical technique to detect and quantify target antigen from ng/ml to pg/ml in 
samples, such as blood, urine and cell culture supernatant. The sandwich ELISA which 
measures the amount of antigen between two layers of antibodies (i.e. capture and detection 
antibody) is more sensitive and specific compared with other ELISA methods. 
The general steps are as follows (Figure 11): 1) a known quantity of capture antibody is 
coated in a 96-well polystyrene plate; 2) non specific binding sites of the coated plate are 
blocked with blocking buffer (i.e. 5% BSA solution); 3) the appropriately diluted sample is 
applied and incubated for 2 hours at room temperature; 4) unbound antigen is washed away 
from the plate; 5) the biotinylated detection antibody that binds specifically to the antigen is 
applied and incubated for 2 hours at room temperature; 6) unbound biotinylated detection 
antibody is washed away from the plate; 7) the horseradish-peroxidase (HRP)-conjugated 
streptavidin which binds to the detection antibody is applied and incubate the plate for 30 
minutes; 8) unbound streptavidin conjugates are washed away from the plate; 9) the substrate 
(1:1 mixture of H2O2 and tetramethylbenzidine), which is converted by HRP into a color, is 
applied and incubated for 15~30 minutes; 10) the absorbance of each well is measured using 
a multiwell spectrophotometer set to 450 nm to determine the presence and quantity of 
antigen. 
In this study, cells were seeded in 48-well plates. After stimulation, the supernatant of cell 
culture was collected. The measurement of VEGF secreted into the cell culture supernatant 
Coated microplate 
Capture Ab 
Target antigen Detection Ab 
Biotin 
HRP 
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was carried out with VEGF ELISA kit (R&D Systems, Wiesbaden, Germany) following the 
manufacturer’s instruction. All experiments were carried out in quadruplicates. 
3.12 Proliferation assay 
Cell proliferation was assessed using the non-radioactive colorimetric WST-1 assay. The Cell 
Proliferation Reagent WST-1 is a clear, slightly red ready-to-use solution, containing 
tetrazolium salt WST-1 and an electron coupling reagent, diluted in sterile phosphate buffered 
saline. This assay is based on the cleavage of WST-1 into formazan dye by mitochondrial 
dehydrogenases in viable cells, and provides a non-radioactive alternative to the [3H]-
thymidine incorporation assay. An expansion in the number of viable cells results in an 
increase in the overall activity of mitochondrial dehydrogenases in the sample. This 
augmentation in enzyme activity leads to an increase in the amount of formazan dye formed, 
which directly correlates to the number of metabolically active cells in the culture. The 
absorbance of the dye solution is measured by a multiwell spectrophotometer (DYNATECH, 
MR5000) at 420-480 nm. 
In this study, 6×103 cells/well TtT/GF cells or 15×103 cells/well AtT20 cells were seeded into 
96-well plates, and 24 hours after transfection of siRNA against RSUME, the cell culture 
medium was changed to DMEM containing 2% FCS and incubated the cells for indicated time 
periods. Then, 10 μl of WST-1 solution was added into the cell culture medium of each well 
and the plate was incubated at 37°C and 5% CO2 for 30 minutes. The absorbance of samples 
was measured by a multiwell spectrophotometer set to 450 nm. All experiments were carried 
out in quadruplicates. 
The effect of RSUME knockdown on cell growth was confirmed by direct cell counting using a 
cell size-adapted coulter counter (Beckman, Z1™ Series COULTER COUNTER®). The cell 
counting was carried out in triplicates.   
3.13 Apoptosis detection  
Apoptosis is characterized by membrane blebbing (zeiosis), condensation of cytoplasm, and 
the activation of an endogenous endonuclease. This nuclease cleaves double-stranded DNA 
at the most accessible internucleosomal linker region, generating mono- and 
oligonucleosomes. In contrast, the DNA of the nucleosomes is tightly complexed with the core 
histones H2A, H2B, H3, and H4, and is thus protected from cleavage by the endonuclease. 
The yielded DNA fragments are discrete multiples of a 180-bp subunit, detected as a “DNA 
ladder” on agarose gels after extraction and separation of the fragmented DNA. The 
enrichment of mono- and oligonucleosomes in the cytoplasm of the apoptotic cell is due to the 
fact that DNA degradation occurs several hours before plasma membrane breakdown.  
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DNA fragmentation as an indicator of apoptosis was measured by a cell death ELISA kit 
(Roche Molecular Biochemicals, Germany) according to the manufacturer’s instruction. All 
experiments were carried out in triplicates. This assay is based on the quantitative “sandwich 
enzyme immunoassay” principle using mouse monoclonal antibodies directed against DNA 
and histones. This allows the specific determination of mono- and oligonucleosomes in the 
cytoplasmic fraction of cell lysates. The samples are placed into a streptavidin-coated 
microplate and incubated with a mixture of anti-histone-biotin and anti-DNA-peroxidase. 
During the incubation interval, nucleosomes will be captured via their histone component by 
the anti-histone-biotin antibody, while binding to the streptavidin-coated microplate. 
Simultaneously, anti-DNA-peroxidase binds to the DNA part of the nucleosomes. After 
removal of the unbound antibodies, the amount of peroxidase retained in the immunocomplex 
is photometrically determined with ABTS as the substrate (Figure 12, Roche Applied science). 
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Figure 12. The principle of the Cell Death Detection ELISA
PLUS
. Panel A: sample 
preparation; Panel B: ELISA. (Roche Applied Science). 
3.14 Statistics 
Results are expressed as mean±SD. The correlation analysis of HIF-1, VEGF and RSUME 
mRNA expression with the tumor grade, age and gender of patients was performed with the 
Fisher exact test, and statistical significance was considered at P < 0. 05. The simple linear 
regression analysis was used to examine the correlation of HIF-1, VEGF and RSUME mRNA 
expression between each other, and a contribution ratio (square of coefficient of determination 
value R2) >0.6 were considered significant. One-way ANOVA was used to compare variables 
in stimulation experiments and HIF-1, VEGF and RSUME mRNA expression in different 
After incubating cells with an apoptosis-
inducing agent, pellet the cells by 
centrifugation (if the cells are adherent cells, 
just remove the culture medium). Retain a 
sample of the supernatant, which may contain 
necrotic DNA that leaked through the 
membrane during incubation. 
Incubate cells with lysis buffer. 
Pellet the intact nuclei by centrifugation. Take 
an aliquot of the supernatant (cell lysate) and 
determine the amount of apoptotic 
nucleosomes present 
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tumor types and normal pituitary glands, and P < 0.05 was considered as significant. The 
statistic analyses were performed with SigmaStat 2.0 (SPSS Inc). 
  
Results 
48 
 
4 Results 
4.1 HIF-1, VEGF and RSUME mRNA expression in human normal pituitaries 
and pituitary adenomas 
RNA were extracted from 3 human normal pituitaries and 31 pituitary adenomas, and then 
quantitative real time RT-PCR was performed to evaluate HIF-1, VEGF and RSUME mRNA 
levels with normalization to the amount of house keeping gene -Actin (Figure 13 A-C).  
Figure 13. mRNA expression levels of HIF-1, RSUME and VEGF in human normal 
pituitaries and pituitary adenomas. Quantitative real time PCR was performed with 31 
human pituitary adenomas and 3 normal pituitaries to detect the mRNA levels of HIF-1 
(A), VEGF (B) and RSUME (C). Values are given as mean±SD (standard deviation) after 
normalization to the amount of -Actin. While the mRNA expression levels of HIF-1, 
RSUME and VEGF in human pituitary adenomas tended to be higher compared with 
normal pituitaries, the difference was not statistically significant, and the difference among 
the various types of adenomas examined was not statistically significant as well. 
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One-way ANOVA statistical analysis showed that the mRNA expression levels of HIF-1, 
RSUME and VEGF in human pituitary adenomas tended to be higher compared with normal 
pituitaries, the difference was not statistically significant, and the difference among the various 
types of adenomas examined was not statistically significant as well, although thyrotroph 
adenomas appeared to produce highest HIF-1, VEGF and RSUME levels. Lowest level of 
HIF-1 and VEGF mRNA were found in non-functioning adenomas and lowest level of 
RSUME was found in prolactinomas.  
Simple linear regression analyses showed that in the pituitary adenomas studied, VEGF and 
RSUME mRNA levels were significantly correlated with HIF-1 mRNA levels (R2=0.6610 or 
R2=0.7296, respectively) (Figure 14 A, B). No significant correlation was found between HIF-
1, VEGF, RSUME mRNA expression and patient age, gender, or tumor grade. 
Figure 14. Correlations of mRNA expression levels among HIF-1, RSUME and 
VEGF in human normal pituitaries and pituitary adenomas. Values are given as 
mean±SD (standard deviation) after normalization to the amount of -Actin. A, B: Simple 
linear regression analyses showed that VEGF and RSUME mRNA levels were 
significantly correlated with HIF-1 mRNA levels in the tested pituitary adenomas 
(R
2
=0.6610 or R
2
=0.7296, respectively). 
4.2 Effect of hypoxia mimicking conditions on RSUME mRNA expression  
In order to test whether RSUME responds to hypoxia in pituitary tumor cells, RSUME mRNA 
expression under hypoxia mimicking conditions was investigated.  
Before stimulation with hypoxia-mimicking agent CoCl2, AtT20 and TtT/GF cells were exposed 
to medium containing only 1% FCS overnight, and then stimulated with 250 μM CoCl2 in the 
same medium. After CoCl2 treatment, RSUME mRNA expression was measured with 
quantitative real time PCR. RSUME mRNA levels in AtT20 and TtT/GF cells were significantly 
increased shortly after CoCl2 treatment and reached the peak at 30 minutes. Maximal 
0 20 40 60
0
10
20
30
R2=0.7296
HIF-1 mRNA
R
S
U
M
E
 m
R
N
A
0 20 40 60
0
2
4
6
R2=0.6610
HIF-1 mRNA
V
E
G
F
 m
R
N
A
A B 
Results 
50 
 
stimulations of 3.22±0.58 and 2.65±0.69 fold versus untreated cells were achieved in AtT20 
and TtT/GF cells, respectively (Figure 15).  
 
Figure 15. RSUME mRNA expression were increased under CoCl2 stimulation in 
AtT20 and TtT/GF cells. AtT20 and TtT/GF cells were stimulated with 250 µM CoCl2. 
RSUME mRNA level was analyzed by quantitative real time PCR in triplicates, and the 
values are given as mean±SD after normalization to -Actin. *, P < 0.05; **, P < 0.01; ***, 
P < 0.001 vs. untreated cells.  
Figure  16. RSUME mRNA expression were increased under CoCl2 stimulation in 
primary human pituitary tumor cells. Primary human pituitary tumor cells were 
stimulated with 125 µM CoCl2. RSUME mRNA level was analyzed by quantitative real 
time PCR in triplicates, and the values are given as mean±SD after normalization to -
Actin. ***, P < 0.001 vs. untreated cells. The similar effect was found in another primary 
non-functioning adenoma cells (data not shown).  
The primary cell cultures of 2 non-functioning adenomas and 1 somatotroph adenoma were 
also tested. Before stimulation, primary human pituitary tumor cells were exposed to tumor 
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medium containing 2% FCS over night, and stimulated with 125 μM CoCl2 in the same 
medium. After CoCl2 treatment, RSUME mRNA expression was measured with quantitative 
real time PCR. RSUME mRNA levels were also significantly increased under CoCl2 treatment 
in all the tested tumor cells (Figure 16 shows the results of 1 non-functioning adenoma and 1 
somatotroph adenoma). Maximal stimulations of 58.80±7.64 and 65.10±8.84 fold versus 
untreated cells were achieved in the non-functioning adenoma and somatotroph adenoma 
shown above, respectively. RSUME mRNA expression reached the peak at 1 hour after 
stimulation. The similar result was found in another non-functioning adenoma (data not 
shown).  
4.3 Effect of hypoxia mimicking conditions on HIF-1 protein expression 
In order to investigate whether HIF-1 can be activated after hypoxia in pituitary tumor cells, 
HIF-1 protein levels under hypoxia mimicking conditions were determined by western blot. 
Before stimulation, TtT/GF and AtT20 cells were exposed to medium containing only 1% FCS 
overnight, and then stimulated in the same medium with CoCl2 of different doses and for 
different time periods. After stimulation, HIF-1 was determined in cell lysates by western blot. 
CoCl2 dose-dependently increased HIF-1 protein levels in both cell lines (Figure 17). With 
stimulation of 5 hours, the maximal HIF-1 expression was achieved at 500 μM CoCl2. The 
stimulatory effect was time-dependent and with the stimulation of 250 µM CoCl2 the maximum 
HIF-1 protein levels were reached after 2 h and 3 h in AtT20 and TtT/GF cell lines, 
respectively (Figure 17). During CoCl2 stimulation, compared with untreated cells, the toxic 
effects of CoCl2 and the changes in cell viability were not observed. 
Figure 17. HIF-1 protein level was increased under CoCl2 stimulation in a 
concentration- and time-dependent manner in AtT20 and TtT/GF cells. AtT20 and 
TtT/GF cells were stimulated with indicated concentrations of CoCl2 and time periods. 
Each image is representative of 3 experiments with similar results. 
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For immunofluorescence studies, after stimulation of 250 µM CoCl2 for 3 hours, AtT20 and 
TtT/GF cells were fixed and immunofluorescence assay for HIF-1 was performed. By 
confocal immunofluorescence microscopy, CoCl2 did not only stimulate expression of HIF-1 
but also its translocation into the nucleus as shown in both cell lines (Figure 18).  
Figure 18. HIF-1 is translocated and accumulated in nucleus after CoCl2 treatment 
in AtT20 and TtT/GF cells. AtT20 and TtT/GF cells were stimulated with 250 µM CoCl2 
for 3 hours. Red color corresponds to HIF-1, and blue color corresponds to nucleus.  
The immunofluorescence images were taken from confocal microscope using 60× and 
20× objectives for AtT20 and TtT/GF cells, respectively. The parameters were fixed when 
taking images by confocal microscopy, and one representative image of 5 observations 
from two independent experiments with similar results is shown. 
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Primary cell cultures of 8 human pituitary adenomas (5 non-functioning, 2 somatotroph 
adenomas, 1 lactotroph adenomas) were also treated with CoCl2 in order to find out whether 
HIF-1 can be activated as in mouse pituitary tumor cell lines. Before stimulation, primary 
tumor cells were exposed to tumor medium containing only 2% FCS overnight, and then 
stimulated in the same medium with CoCl2 of different doses and for different time periods. 
After stimulation, HIF-1 was determined in cell lysates by western blot. HIF-1 protein 
expression was time- and dose-dependently increased after CoCl2 treatment in all the tested 
primary cell cultures (Figure 19 shows the representative findings from two tumor cell cultures). 
Due to limited amount of primary tumor cells, not all the stimulation experiments of different 
doses and time periods could be done in parallel.  
Figure 19. HIF-1 expression was increased under CoCl2 stimulation in a 
concentration- and time-dependent manner in primary human pituitary tumor cells. 
Primary somatotroph adenoma cells were stimulated with different concentrations of 
CoCl2 for 3 h, and primary non-functioning adenoma cells were stimulated with 125 μM 
CoCl2 for different time periods. Each image is representative of 3 experiments with 
similar results. HIF-1 was increased in all the tested primary human pituitary tumor cell 
cultures after CoCl2 treatment, following a time- and concentration-dependent manner. 
Western blots from primary human somatotroph adenoma cells and non-functioning 
adenoma cells were shown as representatives.  
4.4 Effect of hypoxia mimicking conditions on VEGF expression 
VEGF is a well-characterized HIF-1 target and a key factor in angiogenesis. In order to find 
out whether CoCl2 not only induces HIF-1 protein expression but also stimulates VEGF 
secretion, VEGF secretion after CoCl2 stimulation was investigated by VEGF ELISA. 
Before stimulation, TtT/GF and AtT20 cells were exposed to medium containing only 1% FCS 
overnight, and then stimulated in the same medium with CoCl2 of different doses and for 
different time periods. After stimulation, the supernatant of the cell culture was collected and 
VEGF secretion was determined by ELISA. VEGF was significantly increased under CoCl2 
treatment, following a time- and concentration-dependent manner, in TtT/GF cells (Figure 20). 
However, CoCl2 treatment did not significantly stimulate the increase of VEGF secretion in 
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AtT20 cells. From the previous study, it is shown that AtT20 cells have a very high basal 
VEGF production rate (Lohrer, et al. 2001). It may be that the VEGF output by AtT20 cells is 
already saturated and can not be further enhanced under hypoxia mimicking conditions. 
Figure 20. VEGF expression was increased under CoCl2 stimulation in a 
concentration- and time-dependent manner in TtT/GF. TtT/GF cells were stimulated 
with indicated concentrations of CoCl2 and time periods. Values were from ELISA assays, 
and given as mean±SD. **, P < 0.01; ***, P < 0.001 vs. untreated cells. All experiments 
were carried out in quadruplicates. 
VEGF secretion under CoCl2 stimulation in primary cell cultures of 17 human pituitary 
adenomas (11 non-functioning, 3 somatotroph, 2 lactotroph, 1 corticotroph) was also tested. 
Before stimulation, primary tumor cells were exposed to tumor medium containing only 2% 
FCS overnight, and then stimulated in the same medium with different doses of CoCl2 and for 
different time periods. After stimulation, VEGF secretion in the supernatant of culture medium 
was determined by ELISA. CoCl2 dose-dependently increased VEGF secretion in all the 
tested primary tumor cells (Figure 21 A-D show the representative findings). Due to limited 
amount of primary tumor cells, not all the stimulation experiments of different doses and time 
periods could be done in parallel. 
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Figure 21. VEGF expression was increased under CoCl2 stimulation in a 
concentration- and time-dependent manner in primary human pituitary tumor cells. 
Primary human tumor cells were stimulated with indicated concentrations of CoCl2 and 
time periods. Values were from ELISA assays, and given as mean±SD. **, P < 0.01; ***, P 
< 0.001 vs. untreated cells. All experiments were carried out in quadruplicates. 
4.5 Effect of RSUME knockdown on HIF-1 and VEGF production 
4.5.1 In mouse pituitary cell lines 
In order to investigate whether RSUME plays a role in HIF-1 increase after hypoxia in 
pituitary tumor cells, siRNA against mouse RSUME and scrambled siRNA were transfected 
into AtT20 and TtT/GF cells. 24 hours after transfection, the total RNA was extracted and RT-
PCR for mouse RSUME was performed. RSUME mRNA was obviously decreased in both cell 
lines 24 hours after RSUME siRNA transfection compared with un-transfected and scrambled 
siRNA transfected control (Figure 22). 48 hours after transfection of RUSME siRNA and 
scrambled siRNA, AtT20 and TtT/GF cells were stimulated with 250 μM CoCl2 in medium 
containing 1% FCS for 3 hours. After stimulation, HIF-1 was determined in cell lysates by 
western blot. CoCl2-stimulated HIF-1 expression was significantly suppressed in RSUME 
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siRNA transfected AtT20 cells and TtT/GF compared with un-transfected and scrambled 
siRNA transfected control (Figure 23).  
Figure 22. RSUME mRNA expression was suppressed by transfection of siRNA 
against mouse RSUME in AtT20 and TtT/GF cells. AtT20 and TtT/GF cells were 
transfected with siRNA against mouse RSUME, and RT-PCR was performed 24 hours 
after transfection. 
Figure 23. RSUME knockdown suppressed HIF-1 in both TtT/GF and AtT20 cells. 
AtT20 and TtT/GF cells were transfected with mouse RSUME siRNA for 48 h, and then 
treated with 250 μM CoCl2 for 3 h. Each image is representative of 3 experiments with 
similar results. 
For immunofluorescence studies, 48 hours after transfection of RUSME siRNA and scrambled 
siRNA, AtT20 and TtT/GF cells were stimulated with 250 μM CoCl2 in medium containing 1% 
FCS for 3 hours. After stimulation, AtT20 and TtT/GF cells were fixed and 
immunofluorescence assay for HIF-1 was performed. Confocal immunofluorescence 
microscopy showed that the translocation of HIF-1 in response to CoCl2 treatment was 
impaired in AtT20 and TtT/GF cells in which RSUME had been knocked down (Figure 24 and 
Figure 25).  
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Figure 24. HIF-1 was suppressed by RSUME knockdown in AtT20 cells as shown 
by immunofluorescence assay. 48 hours after transfection of RUSME siRNA and 
scrambled siRNA, AtT20 cells were stimulated with 250 μM CoCl2 for 3 hours. Red color 
corresponds to HIF-1, and blue color corresponds to nucleus. The immunofluorescence 
images were taken from confocal microscope using 60× objectives. The parameters were 
fixed when taking images by confocal microscopy, and one representative image of 5 
observations from two independent experiments with similar results is shown. 
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Figure 25. HIF-1 was suppressed by RSUME knockdown in TtT/GF cells as shown 
by immunofluorescence assay. 48 hours after transfection of RUSME siRNA and 
scrambled siRNA, TtT/GF cells were stimulated with 250 μM CoCl2 for 3 hours. Red color 
corresponds to HIF-1, and blue color corresponds to nucleus.  The immunofluorescence 
images were taken from confocal microscope using 20× objectives. The parameters were 
fixed when taking images by confocal microscopy, and one representative image of 5 
observations from two independent experiments with similar results is shown. 
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In order to find out whether RSUME knockdown not only suppresses HIF-1 protein 
expression but also reduces VEGF secretion, VEGF ELISA was performed to determine 
VEGF secretion in AtT20 and TtT/GF cells after transfection of siRNA against RSUME.  
For TtT/GF cells, 48 hours after transfection of RSUME siRNA, cells were treated with 250 μM 
CoCl2 for 24 h, and then the culture supernatant was collected for VEGF ELISA and RNA was 
extracted for RT-PCR. From VEGF ELISA, it was found that RSUME knockdown did not 
significantly reduce the basal VEGF secretion, but significantly decreased CoCl2-stimulated 
VEGF expression. From RT-PCR, VEGF mRNA expression was obviously increased by CoCl2 
stimulation, and was significantly suppressed by RSUME knockdown compared with un-
transfected and scrambled siRNA transfected control (Figure 26) 
 
Figure 26. CoCl2-stimulated VEGF expression was suppressed by RSUME 
knockdown at both protein and mRNA levels in TtT/GF cells. After 48 h transfection of 
RSUME siRNA, TtT/GF cells were treated with 250 μM CoCl2 for 24 h, and then VEGF 
ELISA (A) and RT-PCR (B) were performed to determine VEGF protein and mRNA 
expression. ELISA assay was carried out in quadruplicates and values were given as 
mean±SD. **, P < 0.01. Images of ethidium bromide agarose gel are representatives of 3 
experiments with similar results. 
For AtT20 cells, the effect of RSUME silencing was only tested at basal conditions, as it was 
shown that CoCl2 treatment did not significantly enhance VEGF secretion in this cell line. To 
this end, 48 hours after transfection of RSUME siRNA, the culture supernatant of AtT20 cells 
was collected for VEGF ELISA, RNA from a part of cells was extracted for RT-PCR, and cells 
were also fixed to perform immunofluorescence studies. From VEGF ELISA and RT-PCR, it 
was found that basal VEGF expression was suppressed at both protein and mRNA levels by 
RSUME knockdown compared with un-transfected and scrambled siRNA transfected control 
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(Figure 27).  From Immunofluorescence studies, VEGF staining was obviously weaker in cells 
with RSUME knockdown compared with un-transfected and scrambled siRNA transfected 
control, confirming that RSUME knockdown resulted in a significant reduction of basal VEGF 
expression in AtT20 cells (Figure 28). 
Figure 27. Basal VEGF expression was suppressed by RSUME knockdown at both 
protein and mRNA levels in AtT20 cells. After 48 h transfection of RSUME siRNA, 
VEGF ELISA (A) and RT-PCR (B) were performed to determine VEGF protein and mRNA 
expression. ELISA assay was carried out in quadruplicates and values were given as 
mean±SD. **, P < 0.01. Images of ethidium bromide agarose gel are representatives of 3 
experiments with similar results.  
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Figure 28. Basal VEGF production was suppressed by RSUME knockdown in AtT20 
cells as shown by immunofluorescence assay. After 48 h transfection of RSUME 
siRNA, immunofluorescence was performed to stain VEGF. Red color corresponds to 
VEGF, and blue color corresponds to nucleus. The parameters were fixed when taking 
images by confocal microscopy using 60× objectives, and one representative image of 5 
observations from two independent experiments with similar results is shown. 
4.5.2 In primary human pituitary tumor cell cultures 
RSUME knockdown was applied in primary human pituitary tumor cell cultures to find out 
whether RSUME is implicated in HIF-1 activation as in mouse pituitary cell lines. Due to 
limited amount of primary tumor cells, the experiments on HIF-1 and VEGF expression after 
RSUME knockdown could not be done in parallel. 
Transfection of siRNA in primary human pituitary tumor cells was established for the first time 
in 6 primary cell cultures of human pituitary non-functioning adenomas, and BLOCK-iTTM 
Alexa Fluor
® red fluorescent oligo was used to estimate transfection efficiency. With optimized 
transfection conditions, transfection efficiency was determined to be about 50% by counting 
red fluorescence stained cells in 100 cells 24 hours after transfection of fluorescent oligo 
(Figure 29). RNA was extracted for RT-PCR 24 hours after transfection of RSUME siRNA. 
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From RT-PCR, it was confirmed that 50 nM siRNA against human RSUME obviously 
suppressed RSUME mRNA in primary tumor cells (Figure 30). 
Figure 29. Evaluation of siRNA transfection efficiency in primary human pituitary 
tumor cells. The red fluorescent oligo was transfected into primary cells. 24 hours after 
transfection, the cells were observed under fluorescence microscope, and the number of 
cells with red color was counted in 100 cells to determine the transfection efficiency. The 
images were taken from fluorescence microscope using 10× objectives. 
Figure 30. RSUME mRNA expression was suppressed by transfection of siRNA 
against human RSUME in primary human pituitary tumor cells. The primary human 
non-functioning tumor cells were transfected with siRNA against human RSUME, and RT-
PCR was performed 24 hours after transfection. 
With optimized transfection conditions, RSUME knockdown was also performed in the primary 
human cell cultures of 1 corticotroph adenoma and 1 somatotroph adenoma. 5 days after 
transfection of 20 nM or 50 nM RSUME siRNA, the corticotroph tumor cells were stimulated 
with 125 µM CoCl2 for 3 hours, and then HIF-1 expression in cell lysates was determined by 
western blot. For the primary somatotroph tumor cells, 4 days after transfection of RSUME 
siRNA, cells were stimulated with 125 µM CoCl2 for 24 hours, and then the supernatant of cell 
culture was collected for VEGF ELISA. CoCl2-stimulated HIF-1 protein expression and VEGF 
secretion was significantly suppressed in that corticotroph adenoma and somatotroph 
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adenoma, respectively, compared with scrambled siRNA transfected controls (Figure 31 A, B). 
The suppression of HIF-1 and VEGF expression by RSUME knockdown was not found until 
5 days after transfection of siRNA.       
Figure 31. CoCl2-stimulated HIF-1 and VEGF secretion were suppressed by 
RSUME knockdown in primary human pituitary adenoma cells. The primary human 
corticotroph and somatotroph tumor cells were stimulated with CoCl2 5 days and 4 days 
after transfection of RSUME siRNA, respectively. HIF-1 and VEGF expression were 
determined by western blot in corticotroph tumor cells (A) and by VEGF ELISA in 
somatotroph tumor cells (B), respectively. **, P < 0.01; ***, P < 0.001. 
4.6 Effect of RSUME knockdown on proliferation and apoptosis in mouse 
pituitary cell lines 
During the application of RSUME silencing, it was noticed that a part of cells appeared dead. 
Therefore, the effect of RSUME knockdown on proliferation and apoptosis in pituitary tumor 
cells was studied in AtT20 and TtT/GF cells.  
AtT20 and TtT/GF cells were transfected with RSUME siRNA in 6-well plates. 24 hours after 
transfection, the cells were split into 96-well plates and cultured in medium containing 2% FCS 
for 48 hours. Afterwards, WST-1 assays were performed and the absorbance of samples was 
measured by a multiwell spectrophotometer set to 450 nm. Meanwhile, the cell number was 
also counted using a cell size-adapted coulter counter. By decreased absorbance values from 
WST-1 assay and the decreased cell number, RSUME knockdown significantly suppressed 
cell proliferation in both AtT20 and TtT/GF cells compared with un-transfected and scrambled 
siRNA transfected control (Figure 32 A, B).  
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Figure 32. RSUME knockdown suppressed proliferation in both AtT20 and TtT/GF 
cells. AtT20 and TtT/GF cells were transfected with RSUME siRNA for 72 h, and then cell 
proliferation was determined by WST-1 assay (A) and cell number counting (B). **, P < 
0.01; ***, P < 0.001. The WST-1 assay was carried out in quadruplicates and cell number 
counting was carried out in triplicates. 
RSUME knockdown could be involved in induction of apoptosis besides in the suppression of 
cell proliferation in pituitary tumor cells. Therefore, studies on apoptosis in AtT20 and TtT/GF 
cells were carried out. AtT20 and TtT/GF cells were transfected with RSUME siRNA in 6-well 
plates. 24 hours after transfection, the cells were split into 96-well plates or slides and cultured 
in medium containing 2% FCS for 48 hours. Afterwards, apoptosis-associated DNA 
fragmentation was measured with a specific ELISA in 96-well plates, and the cells on slides 
were fixed to perform immunofluorescence studies on cleaved caspase-3. From cell death 
ELISA, a significant increase of apoptosis-associated DNA fragmentation by RSUME 
knockdown was observed in both AtT20 and TtT/GF cells compared with un-transfected and 
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scrambled siRNA transfected control (Figure 33). From immunofluorescence studies on 
cleaved caspase-3, the active fragment of a well-known pro-apoptotic protein caspase-3, it 
was found that the number of cells with immunoreaction of cleaved caspase-3 strongly 
increased by RSUME knockdown compared with un-transfected and scrambled siRNA 
transfected control in both AtT20 cells (Figure 34) and TtT/GF cells (data not shown). This 
finding indicates that the RSUME knockdown induces pro-apoptotic caspase-3, and thus 
confirms the involvement of RSUME in apoptosis of pituitary tumor cells.  
Figure 33. RSUME knockdown induced apoptosis in AtT20 and TtT/GF cells by cell 
death ELISA.  AtT20 and TtT/GF cells were transfected with RSUME siRNA for 72 h, and 
then cell death ELISA was performed to detect apoptosis-associated DNA fragmentation. 
***, P < 0.001. All the experiments were carried out in triplicates. 
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Figure 34. RSUME knockdown increased cleaved caspase-3 in AtT20 cells. AtT20 
cells were transfected with RSUME siRNA for 72 h, and then immunofluorescence was 
performed to detect cleaved caspase-3. Red color corresponds to cleaved caspase-3, and 
blue color corresponds to nucleus. The images were taken by confocal microscopy using 
10× objectives, and one representative image of 5 observations from two independent 
experiments with similar results is shown (A). The proportion of cells immunopositive for 
cleaved caspase-3 was determined by counting the number of positive cells out of 100 
cells in five different areas of each slice (B). ***, P < 0.001. 
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5 Discussion 
In the present study, the role of the novel sumoylation enhancer RSUME in pituitary 
tumorigenesis was comprehensively studied for the first time. In particular, its co-expression 
with HIF-1and VEGF in pituitary adenomas as well as its implication in the regulation of 
these two potent angiogenesis regulating factors in pituitary tumor cells was investigated. It 
could be demonstrated that RSUME critically regulates HIF-1and VEGF production and thus 
might play an important role in pituitary tumor neovascularization. Moreover, novel functions of 
RSUME on proliferation and survival of pituitary tumor cells have been identified suggesting 
that RSUME is of considerable importance for pituitary tumor development and progression 
and therefore, represents an interesting candidate for development of novel targeted therapies 
for the treatment of pituitary tumors. 
An essential step in the development of any kind of solid tumor is the neovascularization of 
the expanding tumor mass by angiogenesis to supply the tumor cell with enough nutrients and 
oxygen (Carmeliet 2003). The expansion of the tumor mass causes intratumoral cellular 
hypoxia (Harris 2002), which induces the formation of the dimeric transcription factor HIF-1 by 
stabilizing its regulated subunit HIF-1. Activated HIF-1 triggers the expression of VEGF 
protein, which is a key mediator of angiogenesis (Carmeliet 2005). A large number of studies 
have demonstrated that vascularization is more advanced and HIF-1 and VEGF are over-
expressed in the majority of human cancers in comparison to their corresponding normal 
tissues (Ferrara 2004; Zhong, et al. 1999). However, so far little is known about HIF-1 and 
VEGF regulation in pituitary adenomas due to limited and controversial information from few 
immunohistochemistry studies.  
Herein the mRNA expression of RSUME as well as HIF-1 and VEGF was studied in parallel 
in a series of 31 pituitary adenomas by quantitative RT-PCR and the results were compared 
with the findings from 3 normal human pituitaries. Expression analysis at mRNA level had 
been chosen since for comparative analysis at protein level, still no appropriate RSUME 
antibodies are available for immunohistochemistry. RSUME, HIF-1 and VEGF mRNA levels 
were all slightly but not significantly enhanced in pituitary tumors in comparison to normal 
pituitaries. 
This is the first time to show RSUME expression in pituitary adenomas, indicating its 
involvement in pituitary adenoma pathogenesis. Inspired by its function of enhancing HIF-1 
stabilization (Carbia-Nagashima, et al. 2007), if the appropriated RSUME antibodies are 
available, it would be interesting to explore RSUME protein expression in pituitary adenomas 
and its relationship with tumor microvessel density by immunohistochemistry, which could 
offer more evidences about the role of RSUME in angiogenesis of pituitary adenomas.     
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The present study showed HIF-1 mRNA expression in both normal and adenomatous 
pituitaries, whereas one immunohistochemistry study showed no HIF-1 staining in normal 
pituitary gland but distributed HIF-1 staining in pituitary adenomas (Vidal, et al. 2003a). This  
could be explained by previous conclusions that the transcription and synthesis of HIF-1 is 
constitutive but this protein is degraded rapidly in normoxia and stabilized in hypoxia (Ke and 
Costa 2006). The slight increase of HIF-1 mRNA expression in pituitary adenomas 
compared with normal pituitaries shown here underlines that activated HIF-1 up-regulates 
target genes such as PDGF and triggers MAPK and PI3K pathways that contribute to up-
regulating transcription of HIF-1(Semenza 2003; Zhang, et al. 2003). Such autocrine-
signaling pathways are crucial for tumor progression.  
Previous studies from ISH and immunohistochemistry have shown higher VEGF expression in 
the non-tumorous pituitary which is adjacent to tumor tissue compared with pituitary 
adenomas (Lloyd, et al. 1999). In contrast, a RT-PCR study using autopsy-derived pituitary as 
a normal control like in the present study showed the same result as obtained here that VEGF 
expression is higher in pituitary adenomas compared with normal pituitaries (McCabe, et al. 
2002). The differing results between these studies may be caused by different controls. The 
non-tumorous pituitary tissue surrounding the tumor may theoretically be subject to subtle 
changes due to the presence of a tumor, whereas degradation and time to fixation may lead to 
loss of detectable antigens in autopsy tissue (Turner, et al. 2003).   
In contrast to studies in other types of solid tumors, it has been shown that pituitary adenomas 
appear less vascularized than non-tumorous anterior pituitary tissues (Jugenburg, et al. 1995; 
Schechter 1972; Turner, et al. 2000b). However, higher HIF-1 and VEGF expression is 
shown here in adenomatous tissues compared with normal pituitary gland. One of the 
explanations could be that HIF-1 can induce growth factors such as IGF-1 and TGF- to 
activate signal transduction pathways that lead to cell proliferation and survival under hypoxia 
(Feldser, et al. 1999; Krishnamachary, et al. 2003). Moreover, VGEF may not only play a role 
in angiogenesis but may also participate in proliferation and survival of pituitary tumor cells 
through VEGFR-1 as shown in our previous study (Onofri, et al. 2006). Additional, non-
tumorous pituitary tissue which is adjacent to tumor tissue may differ in its characteristics of 
vascularization from normal pituitary gland. Therefore, using normal tissue besides the tumor 
to address vascularization of normal pituitary is not convincible. 
In this study, RSUME, HIF-1 and VEGF mRNA expression is not significantly different 
among the various types of pituitary adenomas examined, which is consistent with previous 
studies. Despite this, there was a tendency that all of them appeared highest level in 
thyrotroph adenomas, and lowest level of HIF-1 and VEGF were found in non-functioning 
adenomas and lowest level of RSUME was found in prolactinomas. One 
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immunohistochemistry study showed strongest staining of HIF-1 in prolactinomas and weak 
staining in corticotroph adenomas (Yoshida, et al. 2005), whereas another 
immunohistochemistry study showed strongest HIF-1 staining in GH-producing adenomas 
and lowest in cortocotroph as well (Vidal, et al. 2003a). Additionally, previous 
immunohistochemistry study with a large cohorts of human pituitary adenomas showed 
strongest VEGF staining in GH, corticotroph, silent corticotroph, silent subtype3, and non-
oncocytic null cell adenomas and relatively weak staining in PRL, gonadotroph and thyrotroph 
adenomas (Lloyd, et al. 1999), whereas another study by RT-PCR showed strongest VEGF 
staining in thyrotroph adenomas and lowest in GH-producing adenomas (Kim, et al. 2005). 
The present study could not confirm the results from the study mentioned above, and this is 
probably due to different investigating technology and limited sample number, and different 
classification of non-functioning adenomas. These controversial previous reports together with 
present study indicate that HIF-1 and VEGF expression are not associated with pituitary 
adenoma histotypes. Whether RSUME expression has significant relationship with types of 
pituitary adenomas need to be clarified with more samples.   
An immunohistochemistry study on angiogenesis by measurement of microvessel density 
(MVD) in pituitary adenomas showed highest and lowest MVD in thyrotroph adenomas and 
prolactinomas, respectively (Niveiro, et al. 2005). In the present study, RSUME mRNA 
expression level is highest in thyrotroph adenomas and lowest in prolactinomas, which is 
probably correlated with the MVD reported in the study mentioned above; however, relatively 
low level of RSUME mRNA expression did not correlate with relatively high MVD in non-
functioning adenomas (Niveiro, et al. 2005). Although in the present study HIF-1 and VEGF 
mRNA expression were highest in thyrotroph adenomas as well, they showed lowest level in 
non-functioning adenomas which have high MVD reported in some studies (Niveiro, et al. 
2005; Turner, et al. 2000b). It was concluded that the present study could not correlate the 
HIF-1, VEGF mRNA expression with the microvessel density of pituitary adenomas 
described in previous study. This conclusion is consistent with other studies. One study using 
RT-PCR showed higher levels of HIF-1 expression in pituitary carcinomas and GH-producing 
adenomas (Vidal, et al. 2003a), the most and least vascularized pituitary tumors ,respectively, 
which was shown by another study (Vidal, et al. 2001). And a high rate of HIF-1 has been 
shown in cases of non-small cell lung cancer with both high and low MVD (Giatromanolaki, et 
al. 2001). This could be explained by the hypothesis that HIF-1 is required not for vessel 
formation but for the regular distribution of the vascular network, and disordered vasculature 
causes microenvironmental hypoxia which induces HIF-1activity (Vidal, et al. 2003a; Yu, et 
al. 2001). A study based on microvessel structural entropy has shown that rather than 
microvessel density, regular and less chaotic microvascular geometry contributes to increased 
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cell proliferation activity in PRL-producing tumors. This conclusion indicates that the 
interactions between vascular supply and pituitary tumor cell behavior may not be fully 
explained only by microvessel density (Vidal, et al. 2003a; Vidal, et al. 2003b). On the other 
hand, most of patients with prolactinomas or somatotroph adenomas have the history of 
dopamine agonist or somatostatin treatment that show anti-angiogenic effects (Gomez, et al. 
2006; Novella-Maestre, et al. 2009), which probably leads to alteration in HIF-1, VEGF and 
RSUME expression. Therefore, it is necessary to perform separate studies for treated and 
untreated adenomas, and otherwise a comparison may not be valid.  
Consistent with previous study, no correlation was found in the present study between HIF-1, 
VEGF expression and tumor grade, age and gender of patients (Viacava, et al. 2003; Vidal, et 
al. 2003a), and RSUME mRNA expression also did not correlate with these parameters. A 
relationship between tumor size and MVD in prolactinomas has been shown, and 
microprolactinomas were less vascular than macroprolactinomas; in contrast, there was no 
such a difference between vascular densities of microadenomas and macroadenomas 
producing GH (Turner, et al. 2000b). No significant difference was found in MVD between 
invasive and non-invasive pituitary adenomas (Jugenburg, et al. 1995; Vallar, et al. 1987), 
whereas another study showed significant higher MVD in invasive than non-invasive PRL-
producing adenomas but not in GH and ACTH-producing adenomas (Vallar, et al. 1987). 
Therefore, it seems that HIF-1, VEGF and RSUME expression and even MVD are not 
significantly implicated in pituitary adenoma behavior. However, HIF-1, VEGF and MVD are 
significantly higher in pituitary carcinoma than adenomas (Jugenburg, et al. 1995; Lloyd, et al. 
1999; Turner, et al. 2000a; Vidal, et al. 2003a), indicating the up-regulation of HIF-1 and 
VEGF during pituitary tumor progression and also a relationship between aggressive pituitary 
behavior and angiogenesis. 
Based on previous observations that RSUME acts through enhancing sumoylation on HIF-1 
expression (Carbia-Nagashima, et al. 2007) and thus probably on angiogenesis-regulating 
VEGF, correlation analyses among RSUME, HIF-1 and VEGF mRNA expression were 
performed in pituitary tumors. HIF-1 mRNA significantly and positively correlated with 
RSUME and VEGF mRNA expression in pituitary tumors indicating an interrelationship among 
these factors in pituitary adenomas.  
Regulation of VEGF expression has been studied previously in pituitary adenomas, and it has 
been shown that several stimuli such as IL-6, estradiol and pituitary adenylate cyclase 
activating peptide (PACAP) up-regulate VEGF expression (Banerjee, et al. 1997; Gloddek, et 
al. 1999), whereas glucocorticoids inhibit VEGF (Lohrer, et al. 2001). However, whether VEGF 
can be induced in pituitary adenomas by hypoxia through HIF-1 signaling pathway involving 
RSUME has not yet been studied.  
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In the present study, CoCl2 was chosen to simulate hypoxia condition. CoCl2 is a well 
established hypoxia mimicking substance (Ebert and Bunn 1999; Webb, et al. 2009). Co2+ are 
thought to mimic the hypoxia by binding instead of Fe2+ to the heme molecules which are 
regarded as oxygen sensors in both mammalian and bacteria, causing decreased oxygen 
affinity due to a conformational change (Ebert and Bunn 1999; Goldberg, et al. 1988). 
Additionally, It has been shown that sharing similar mechanism in hypoxia Co2+ are able to 
stabilize HIF-1 in normoxia by substituting Fe2+ from the Fe2+ -binding site of PHDs, leading 
to inhibition of PHDs activity (Masson and Ratcliffe 2003), and Co2+ inhibits the Interaction 
between HIF-1 and VHL Protein by direct binding to HIF-1(Yuan, et al. 2003) Moreover, 
like in hypoxia, Co2+ activates mRNA transcription of hypoxia response genes such as 
erythropoietin, glycolytic enzymes and VEGF by stimulating reactive oxygen species (ROS) 
generation, although mitochondrial-dependent ROS generation was found in hypoxia but not 
found after Co2+ exposure (Chandel, et al. 1998).  
In order to test whether RSUME responds to hypoxia in pituitary tumor cells, stimulation with 
CoCl2 was performed. RSUME mRNA expression was shown to increase within 30 minutes 
after CoCl2 stimulation and to go down within 2 hours  in mouse pituitary cell lines and primary 
human pituitary adenoma cell cultures. This is not paradoxical in view of the results obtained 
for HIF-1which reached its accumulation peak 2 hours after the onset of CoCl2 stimulation. 
As shown in the previous study, RUSME enhances HIF-1 stabilization by facilitating SUMO 
transfer (Carbia-Nagashima, et al. 2007), therefore RSUME mRNA expression is probably 
down-regulated after SUMO chain formation. Due to lack of proper antibody of RSUME, 
determination of RSUME at protein level could not be performed. 
It was next tested whether CoCl2 induces HIF-1 and VEGF in mouse pituitary cell lines and 
as well as in primary cell cultures of human pituitary adenomas. As shown in other cell types 
(Liu, et al. 1999; Okada, et al. 1998; Shima, et al. 1995; Steinbrech, et al. 2000; Webb, et al. 
2009), CoCl2 treatment time- and dose-dependently stimulated HIF-1 protein expression in 
AtT-20, TtT/GF cell lines and all the tested human pituitary adenoma cultures, and HIF-1 
accumulation in nucleus was shown in both AtT20 and TtT/GF cells. A significant rise in VEGF 
release by CoCl2 stimulation following a time- and dose- dependent manner was found in 
TtT/GF cells and all the human pituitary adenoma cell cultures, indicating that HIF-1 can be 
induced and activated in hypoxia-mimicking conditions in pituitary adenoma cells.  
Since neither RSUME inhibitors nor neutralizing antibodies are actually available, RSUME 
was down regulated by siRNA technology to further clarify the involvement of RSUME in 
regulation of HIF-1 and VEGF in pituitary adenomas. Transfection of siRNA in primary 
human pituitary tumor cells was established for the first time. siRNA against RSUME strongly 
down-regulated RSUME expression examined by RT-PCR and significantly reduced the HIF-
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1 expression in both mouse pituitary cell lines and primary human pituitary tumor cells. 
Additionally, it was shown that the RSUME knockdown abolished nucleus accumulation of 
HIF-1in both AtT20 and TtT/GF cell lines, and also decreased CoCl2-stimulated VEGF 
secretion in TtT/GF cells and primary human pituitary tumor cells. These findings suggest that 
RSUME is required in HIF-1 activation in pituitary tumor cells under hypoxia-mimicking 
conditions. Although all these experiments with CoCl2 need to be confirmed under real 
hypoxic conditions at 1% oxygen, the results shown here already point to an essential role of 
RSUME in the induction of angiogenic processes in pituitary adenomas, and probably other 
types of solid tumors.  
In the present study, a significant rise in VEGF release by CoCl2 stimulation was not found in 
AtT20 cells, but RSUME knockdown significantly decreased basal secretion of VEGF in AtT20 
cells. It is known that AtT20 cells basally secrete the highest level of VEGF compared with 
other pituitary tumor cell lines such as TtT/GF, GH3 and T3-1 (Lohrer, et al. 2001). From 
previous studies, VEGF is also regulated by other mechanisms besides hypoxia. It has been 
demonstrated that the gene promoter of VEGF contains consensus binding sites for 
transcription factor -catenin/TCF complex, and VEGF is up-regulated by transfection of 
normal colon epithelial cells with activated -catenin (Easwaran, et al. 2003). The 
transcriptional activity of -catenin/TCF complex is reduced when TCF-4 lacks SUMO 
attachment sites, suggesting that sumoylation activates -catenin/TCF (Yamamoto, et al. 
2003). Activated -catenin/TCF signaling may be responsible for the constitutively high 
secretion of VEGF by AtT20 cells, and CoCl2 induced HIF-1 accumulation may not be able 
further stimulate already saturated VEGF production. Additionally, RSUME knockdown in 
AtT20 cells probably leads to lack of sumoylation of TCF-4, and thus abolishes the activity of 
-catenin/TCF, which results in decreased VEGF expression.  
Since RSUME has been detected only recently, little is known about other functions beyond 
its action on HIF-1 stabilization and thus, angiogenesis. Interestingly, it was found that a part 
of cells were floating after RSUME knockdown, whereas the control cells without RSUME 
silencing had no changes. Therefore, the putative role of RSUME is implicated in the 
regulation of proliferation and survival was investigated in the present study for the first time. 
RSUME knockdown by siRNA in pituitary tumor cell lines led to a significant suppression of 
proliferation as shown by WST-1 assay and direct cell number counting. Cell death ELISA and 
detection of cleaved caspase-3 proved that apoptosis was induced by RSUME knockdown. 
This would mean that in pituitary adenomas in which RSUME is present and probably over-
expressed, this factor would stimulate pituitary adenoma cell proliferation and would prevent 
intratumoral apoptosis and thus in total would support pituitary adenoma progression.  
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Some apoptosis key regulators involved in human cancers which have been shown to be 
regulated by sumoylation may be affected also in pituitary tumor cells by the sumoylation 
enhancer RSUME (Alarcon-Vargas and Ronai 2002; Kim and Baek 2006). For instance, it has 
already been demonstrated, that RSUME can block the transcriptional activity of nuclear 
factor-B (NF-B) by enhancing the sumoylation of IB (Carbia-Nagashima et al. 2007). 
Sumoylated IB escapes from ubiquitin-mediated degradation and acts as the inhibitor of NF-
B. NF-B generally acts as a tumor promoter through up-regulating anti-apoptotic proteins; 
however it is sometimes pro-apoptotic depending on cell types, stimuli as well as the subunit 
involved (Radhakrishnan and Kamalakaran 2006). It has been shown that inhibition of NF-B 
activity combined with expression of oncogenic Ras in epidermal keratinocytes leads to 
invasive neoplasia with features similar to those of squamous cell carcinoma (Dajee, et al. 
2003; Dutta, et al. 2006; Kim and Baek 2006). From our previous study, NF-B is expressed in 
normal anterior pituitary and in pituitary adenomas and facilitates the inhibitory effect of 
interferonon POMC gene transcription in AtT20 cells (Labeur, et al. 2008). It is speculated 
that NF-B activation by RSUME knockdown could be responsible for the here observed 
apoptosis induction in pituitary tumor cells.  
The sumoylation of the important tumor suppressor p53 is well studied. It has been 
demonstrated that PIAS1 (protein inhibitor of activated STAT-1), which is an E3-like ligase, 
promotes sumoylation of p53 and in this way represses its transcriptional activity, suggesting 
that sumoylation of p53 restricts its ability to control cell death and/or growth (Alarcon-Vargas 
and Ronai 2002; Schmidt and Muller 2002). Furthermore, Mdm2 which mediates ubiquitination 
and degradation of p53 is also SUMO-modified (Alarcon-Vargas and Ronai 2002; Buschmann, 
et al. 2000). Sumoylation of Mdm2 enhances its stabilization and increases its activity of 
mediating degradation of p53 through ubiquitination (Buschmann, et al. 2000). Therefore, it 
was speculated that the activation of p53 by RSUME silencing through abolished sumoylation 
of p53 and Mdm2 contributes to apoptosis induction in pituitary tumor cells.   
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Alternatively, the pro-apoptotic effects of RSUME knockdown on pituitary adenoma cell 
proliferation may be explained by the down-regulation of HIF-1 and VEGF, since HIF-1 and 
VEGF not only promote angiogenesis but also facilitate cell proliferation and survival (Feldser, 
et al. 1999; Krishnamachary, et al. 2003; Lee, et al. 2004; Onofri, et al. 2006). Through 
supporting pituitary tumor neovascularization and growth in parallel, RSUME might enhance 
pituitary adenoma progression and therefore represents a putative therapeutic target for the 
development of novel concepts for the treatment of human pituitary tumors (Figure 35). 
Figure 35. Schematic model for the role of RSUME on pituitary tumor pathogenesis. 
It is proposed that RSUME enhances pituitary tumor progression through supporting 
tumor angiogenesis and growth as well as inhibiting tumor cell apoptosis. 
Sumoylation consequences are variable with different substrates and different cell types, and 
therefore sumoylation may promote or inhibit tumor progression. In Wnt signaling pathway, 
sumoylation of TCF-4 enhances its transcriptional activitythus enhances its target gene 
expression, including some proto-oncogenes such as c-Myc, c-jun and cyclin-D1 (He, et al. 
1998; Mann, et al. 1999; Tetsu and McCormick 1999; Yamamoto, et al. 2003). SUMO-
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conjugating enzyme Ubc9 is over-expressed in several human tumors such as lung 
adenocarcinoma, ovarian carcinoma and melanoma, and several approaches to target Ubc9 
functions are in experimental phases to explore the therapeutic application (Hoeller and Dikic 
2009). However, sumoylation may reversely suppress tumor progression. It has been shown 
that sumoylation negatively regulates c-jun activity, thereby limits its oncogenic capacity 
(Muller, et al. 2000).  Additionally, arsenic trioxide, which stimulates degradation of oncogenic 
fusion protein PML-RAR- by enhancing its sumoylation, is currently used in clinics as an 
efficient therapeutic agent for the treatment of patients with APL (acute promyelocytic 
leukemia) (Hoeller and Dikic 2009). As a sumoylation enhancer, RSUME could adopt both 
tumor-promoting and tumor-suppressing roles, and it would be meaningful to perform more 
extensive studies on the exploration of RSUME actions and putative therapeutic strategies not 
only in human pituitary tumors but also in other types of human cancers. 
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6 Summary 
Despite considerable progress, neither the processes involved in the genesis nor the 
mechanisms triggering the progression of pituitary adenomas are well understood. A large 
number of studies have shown that HIF-1and VEGF play essential roles in growth and 
progression of a wide variety of solid tumors by promoting tumor neovascularization. However, 
so far only few reports focus on the role of these two most powerful, hypoxia-induced 
angiogenic factors in slowly growing and poorly vascularized pituitary adenomas. RSUME was 
recently isolated from experimentally induced pituitary tumors in nude mice, and was shown to 
increase stability and transcriptional activity of HIF-1 in monkey kidney cell line COS-7 by 
acting as a sumoylation enhancer. These findings suggest a putative role of RSUME in 
pituitary tumor formation and progression.  
In the present study, the pathological role of RSUME in angiogenesis and progression of 
pituitary adenomas was studied for the first time in mouse pituitary cell lines AtT20 and TtT/GF 
as well as in human pituitary adenoma cells. 
By real-time quantitative PCR, it was demonstrated that RSUME, HIF-1 and VEGF mRNA 
expression tended to be over-expressed in human pituitary adenomas compared with the 
expression levels in normal pituitaries. However, no significant differences among adenoma 
types, tumor grade, age or gender of patients were observed. Nevertheless, correlation 
analyses showed that HIF-1 mRNA level was significantly correlated with VEGF and RSUME 
mRNA levels in the examined pituitary adenomas, giving the first evidence for the interference 
of RSUME with the two major angiogenic factors and thus, with pituitary adenoma 
neovascularization.    
To further explore the angiogenic role of RSUME, the hypoxia-mimicking substance CoCl2 
was applied in mouse pituitary cell lines and primary human pituitary tumor cell cultures to 
investigate the regulatory role of RSUME on HIF-1 and VEGF. Under CoCl2 treatment, 
RSUME mRNA expression was significantly enhanced and HIF-1with translocation into 
nucleus was remarkably increased at protein level. The increased transcriptional activity of 
HIF-1was demonstrated by a significant elevation of the VEGF production in pituitary tumor 
cells.  In order to test whether RSUME was implicated in up-regulation of HIF-1 and VEGF 
under hypoxia-mimicking conditions, the corresponding experiments were performed after 
RSUME knockdown using the siRNA technology. This approach was not only performed in 
easily transfectable pituitary tumor cell lines but also for the first time in primary cell cultures of 
human pituitary adenomas. RSUME knockdown significantly suppressed HIF-1 and VEGF 
expression in mouse pituitary tumor cell lines and primary cell cultures of human pituitary 
adenomas, indicating that RSUME is critically involved in pituitary tumor angiogenesis through 
regulating HIF-1 and VEGF production.  
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As changes in pituitary tumor cell viability were noticed after RSUME silencing, this factor may 
have additional functions in pituitary tumors. Indeed, RSUME knockdown was shown to inhibit 
pituitary tumor cell proliferation and to enhance the apoptosis in these cells. Therefore, in 
addition to its pro-angiogenic action, RSUME has proliferative and anti-apoptotic activities in 
pituitary tumor cells. 
In conclusion, the findings of the present study suggest that, the novel protein RSUME is an 
important player in pituitary tumor pathogenesis by supporting intratumoral angiogenesis, 
stimulating pituitary tumor cell proliferation and inhibiting tumor cell apoptosis. Therefore, this 
factor could represent a novel future target for the development of new concepts for the 
treatment of pituitary tumors.   
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8 Abbreviations 
2-OG 2-oxoglutarate 
-MSH Alpha-melanocyte stimulating hormone 
ACTH Adrenocorticotropic hormone 
AHR Aryl hydrocarbon receptor 
AIP Aryl hydrocarbon receptor interacting protein 
APL Acute promyelocytic leukemia 
ARD1 Arrest-defective-1 
AVP Arginine vasopressin 
ARNT Aryl hydrocarbon receptor nuclear translocator 
bFGF Basic fibroblast growth factor 
bHLH Basic helix-loop-helix 
CD31 Platelet endothelial cell adhesion molecule 
CDK Cyclin-dependent kinase 
CDKI Cyclin-dependent kinase inhibitor 
CRH Corticotropin-releasing hormone 
D2R Dopamine 2 receptor 
EC Endothelial cell 
ECM Extracellular matrix 
ER Estrogen receptor 
F8 Endothelial antigens factor eight-related antigen 
FIH Factor inhibiting HIF-1 
FS Folliculostellate cell 
FSH Follicle-stimulating hormone 
GFPA Glial fibrillary acidic protein 
GH Growth hormone 
GHRH Growth-hormone-releasing hormone 
GnRH Gonadotropin-releasing hormone 
GR Glucocorticoid receptor 
HIF-1 Hypoxia inducible factor-1 
HRE Hypoxia response element 
Abbreviations 
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IGF-1 Insulin-like growth factor-1 
IL-6 Interleukin-6 
LH Luteinizing hormone 
LOH Loss of heterozygosity 
MAPK Mitogen-activated protein kinase 
MEN1 Multiple endocrine type 1 
MMP Matrix metalloproteinase 
mTOR Mammalian target of rapamycin 
MVD Microvessel density 
NF-B Nuclear factor-B 
NGF Nerve growth factor 
ODDD Oxygen-dependent degradation domain 
PAS domain Per-ARNT-Sim domain 
PAS stain Periodic acid-Schiff stain 
PDGF Platelet-derived growth factor 
PHD Prolyl hydroxylase 
PI3K Phosphatidylinositol 3-kinase 
PIAS1 Protein inhibitor of activated STAT-1 
Pit-1 Pituitary transcription factor 1  
PKA Protein kinase-A 
PML Promyelocytic leukemia protein 
POMC Pro-opiomelanocortin 
pRb Retinoblastoma protein 
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Prop1 Prophet of pituitary transcription factor 1 
PTAG Pituitary tumor apoptosis gene 
PTTG Pituitary tumor transforming gene 
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SUMO Small ubiquitin-related modifier 
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TAD Transactivation domain 
TGF- Transforming growth factor-beta 
Tpit-1 T-box transcription factor 
TR Thyroid hormone receptor  
TRH Thyrotropin-releasing hormone 
TSH Thyroid-stimulating hormone 
Ubc9 Ubiquitin-conjugating 9 
UEA1 Ulex europaeus agglutinin 1 
VEGF Vascular endothelial growth factor 
VHL Von Hippel-lindau  
VSMC Vascular smooth muscle cell 
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